Title: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with 
Cortisol -Secreting Adrenal  Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, 
Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant  
 
 
Study ID: [REMOVED] 
 Date:  11 October 2024 
 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 12 of 105 CONTENTS 
CLINICAL STUDY PROTOCOL CORT125134-456 .................................................................. 1  
SPONSOR SIGNATURE PAGE ................................................................................................... 2  
SYNOPSIS ...................................................................................................................... ................ 3 
CONTENTS ...................................................................................................................... ............ 12 
LIST OF TABLES ................................................................................................................ ........ 18 
LIST OF FIGURES ............................................................................................................... ....... 18 
LIST OF ABBREVIATIONS AND DEFINITIONS ................................................................... 19  
1 INTRODUCTION: BACKGROUND INFORMATION AND 
SCIENTIFIC RATIONALE ............................................................................................. 22  
1.1 Therapeutic  Area .............................................................................................................. . 22 
1.2 Relacorilant .................................................................................................................. ..... 24 
1.3 Clinical Summary ............................................................................................................. 24 
1.3.1 Phase 1 Studies ..................................................................................................... 25  
1.3.2 Phase 2 Study ........................................................................................................ 25  
1.4 Rationale for Study Design and Dose Regimen ............................................................... 27  
1.4.1 Design Considerations .......................................................................................... 27  
1.4.2 Rationale for Dose Sele ction and Regimen .......................................................... 27  
1.5 Risk/Benefit Assessment .................................................................................................. 28  
2 STUDY OBJECTIVES ..................................................................................................... 32  
2.1 Primary Objectives............................................................................................................ 32 
2.2 Secondary Objective ......................................................................................................... 3 2 
2.3 Exploratory Objectives ..................................................................................................... 32  
3 STUDY DESIGN.............................................................................................................. 33  
3.1 Overall Design ................................................................................................................ .. 33 
3.2 Study Endpoints ............................................................................................................... . 33 
3.2.1 Primary Endpoints ................................................................................................ 33  
3.2.2 Secondary Endpoints (fr o
m Baseline to Week 22/ET, compared between 
relacorilant a nd placebo) ....................................................................................... 33  
3.2.3 Exploratory Efficacy Endpoints ............................................................................ 34  
3.3 Number of Patients and Study Duration ........................................................................... 35  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 13 of 105 3.3.1 Number of Patients ............................................................................................... 35  
3.3.2 Study Duration ...................................................................................................... 35  
3.3.3 Discontinuation of Study Sites.............................................................................. 35  
3.4 Definitions......................................................................................................................... 35 
3.4.1 Enrollment............................................................................................................. 35 
3.4.2 End of Treatment .................................................................................................. 35  
3.4.3 Patient Study Completion ..................................................................................... 35  
3.4.4 End of Study ......................................................................................................... 35  
3.5 Treatment Continuation .................................................................................................... 36  
3.6 Study Termination by Sponsor ......................................................................................... 36  
4 STUDY POPULATION ................................................................................................... 37  
4.1 Inclusion Criteria .............................................................................................................. 37 
4.2 Exclusion Criteria ............................................................................................................ . 37 
4.3 Screen Failures ............................................................................................................... ... 38 
4.4 Early Patient Discontinua tion or Withdrawal ................................................................... 39  
4.5 Replacement of Patients .................................................................................................... 40  
4.6 Restrictions During Study ................................................................................................. 40  
4.6.1 Dietary Restrictions .............................................................................................. 40  
4.6.2 Contraception ........................................................................................................ 40  
4.6.3 Surgery during the Study ...................................................................................... 40  
5 STUDY TREATMENTS AND MANAGEMENT .......................................................... 41  
5.1 Study Drug and Placebo.................................................................................................... 41  
5.2 Non-Investigational Medicinal Agent............................................................................... 42  
5.3 Dose-Escalation Process ................................................................................................... 42  
5.4 Dose Modifications ........................................................................................................... 43
 
5.4.1 Dose Interruption and/or Discontinua tion: Special Safety Events ....................... 43  
5.4.2 Pharmacokinetic Criteria for Dose Adjustment or Discontinuation ..................... 45  
5.5 Concomitant Medications ................................................................................................. 45  
5.5.1 Rules for Use of Antidiabetic and Antihype rtensive Concomitant Medications .. 46  
5.5.1.1 Decrease or Discontinuation of Concomitant Medications ................... 46  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 14 of 105 5.5.1.2 Increase or Initiation of Concomitant Medication ................................. 47  
5.6 Prohibited Medications ..................................................................................................... 48  
5.7 Method of Treatment Assignment and Randomization .................................................... 49  
5.8 Blinding/Unblinding ......................................................................................................... 49 
5.9 Dosing Diary .................................................................................................................. ... 50 
5.10 Product Accountability and Tr eatment Adherence ........................................................... 50  
5.11 Continued Access to Study Treatment .............................................................................. 50  
5.12 External Data Review Committee .................................................................................... 51  
5.12.1 Independent Data-Monitoring Committee to Monitor Patient Safety .................. 51  
5.13 Monitoring of and Treatment for Elect rolyte Abnormalities and Edema ......................... 51  
6 DESCRIPTION OF STUDY ASSESSMENTS AND PROCEDURES ........................... 52  
6.1 Informed Consent and Screening ...................................................................................... 52  
6.1.1 Dexamethasone Suppression Test......................................................................... 52  
6.1.2 Adrenal-Imaging History ...................................................................................... 52  
6.1.3 History Cushing- 6\QGURPH‡ØÖ0HGLFDWLRQ:DVKRXW  ............................................... 52 
6.1.4 Demographics and Baseline Disease Characteristics ........................................... 53  
6.1.5 Medical and Medication History .......................................................................... 53  
6.2 Safety Assessments ........................................................................................................... 53 
6.2.1 Physical Examination............................................................................................ 53 
6.2.2 Vital Signs ............................................................................................................. 53  
6.2.3 Height, Weight, and Waist Circumference ........................................................... 54  
6.2.4 Electrocardiogram ................................................................................................. 54  
6.2.5 Adverse Ev ents ..................................................................................................... 54  
6.2.6 Concomitant Medications ..................................................................................... 55 
6.2.7
 Clinical Laboratory Assessments .......................................................................... 55  
6.2.7.1 Laboratory Parameters ........................................................................... 55  
6.2.7.2 Sample Collection, Prepar ation, and Shipping ...................................... 56  
6.2.7.3 Blood-Volume Summary ....................................................................... 57  
6.3 Pregnancy Test ................................................................................................................ .. 57 
6.4 Efficacy Assessments........................................................................................................ 57  
6.4.1 Glucose Tolerance ................................................................................................ 58  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 15 of 105 6.4.2 Ambulatory Blood Pressure Monitoring (ABPM) ................................................ 58  
6.4.3 Glycated Hemoglobin (HbA1c) ............................................................................ 59  
6.4.4 Hypothalamic-Pituitary-Adrenal  Axis Parameters ............................................... 59 
6.4.4.1 Plasma ACTH ........................................................................................ 59  
6.4.4.2 Plasma DHEA-S .................................................................................... 59  
6.4.4.3 Fasting Serum Cortisol .......................................................................... 59  
6.4.5 Sit-to-Stand Test ................................................................................................... 59  
6.4.6 Trail-Making Test ................................................................................................. 59 
6.4.7 Biochemical Markers of  Bone Remodeling .......................................................... 60 
6.4.8 DXA Scans............................................................................................................ 60  
6.5 Pharmacodynamic Assessments ....................................................................................... 60  
6.5.1 Urinary Free Cortisol (UFC) ................................................................................. 60  
6.5.2 Late-Night Salivary Cortisol ................................................................................. 60  
6.5.3 Early-Morning Salivary Cortisol .......................................................................... 61  
6.6 Patient-Reported Outcomes .............................................................................................. 61  
6.6.1 Cushing QoL Questionnaire ................................................................................. 61  
6.6.2 Beck Depression Inventory-II ............................................................................... 61  
6.7 Pharmacokinetic (PK)  Assessments ................................................................................. 61 
6.8 Pharmacodynamic/Biomark er Assessments ..................................................................... 62 
6.9 Appropriateness of the Measures ...................................................................................... 62  
6.10 Blood Storage.................................................................................................................... 62 
7 STUDY ASSESSMENTS AND PROCEDURES BY STUDY VISIT ............................ 63  
7.1 Scheduled Visits................................................................................................................ 63 
7.1.1 6FUHHQLQJ9LVLW√≠WR√≠GD\  ............................................................................ 64 
7.1.2  Baseline Visit (Day 1)
 ........................................................................................... 65  
7.1.3 Week 2 (¬±7 days) .................................................................................................. 66  
7.1.4 Week 6 (¬±7 days) .................................................................................................. 67  
7.1.5 Week 10 (¬±7 days) ................................................................................................ 68  
7.1.6 Week 14 (¬±7 days) ................................................................................................ 68  
7.1.7 Week 18 (¬±7 days) ................................................................................................ 69  
7.1.8 Week 22 (-14/+7 days) ......................................................................................... 70  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 16 of 105 7.1.9 Early-Termination Vi sit (+14 days) ...................................................................... 71  
7.1.10 Follow-Up Visit (¬±7 days) .................................................................................... 72  
7.2 Unscheduled Visits ........................................................................................................... 72 
8 SAFETY EVENT DOCUMENTATION AND REPORTING ........................................ 73  
8.1 Investigator‚Äôs Responsibilities .......................................................................................... 73  
8.2 Definition of an Adverse Event ........................................................................................ 73  
8.3 Definition of a Serious  Adverse Event ............................................................................. 73  
8.4 Expectedness ..................................................................................................................... 74 
8.5 Clinical-Laboratory Adverse Events ................................................................................. 74  
8.6 Documentation of Adverse Events ................................................................................... 74  
8.7 Adverse Event Classification ............................................................................................ 75  
8.7.1 Intensity Grades of Adverse Events ...................................................................... 75  
8.7.2 Relationship of Adverse Event to Study Drug or Procedure ................................ 75  
8.8 Procedures for Reporting a Serious Adverse Event .......................................................... 76  
8.9 Disease-Related Events and/or Disease-Rela ted Outcomes Not Qualifying as AEs or SAEs
........................................................................................................................................... 76 
8.10 Adverse Event Follow-Up ................................................................................................ 76  
8.11 Pregnancy ..................................................................................................................... ..... 76 
8.11.1 Maternal Exposure ................................................................................................ 76  
8.11.2 Paternal Exposure ................................................................................................. 77  
8.12 Treatment of Overdose ..................................................................................................... 77  
8.13 Emergency Sponsor Contact ............................................................................................. 77  
9 STATISTICAL METHODS ............................................................................................. 78  
9.1 Analysis Populations ......................................................................................................... 78 
9.2 General Statistical Consi derations
 .................................................................................... 78  
9.3 Hypothesis Testing............................................................................................................ 78 
9.4 Sample-Size Calculation ................................................................................................... 79  
9.5 Analysis Plan ................................................................................................................. ... 80 
9.5.1 Patient Disposition ................................................................................................ 80  
9.5.2 Demographic and Baseline Characteristics Data .................................................. 80  
9.5.3 Prior and Concomitant  Medications ..................................................................... 80  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 17 of 105 9.5.4 Analysis of Efficacy Endpoints ............................................................................ 80  
9.5.4.1 Analysis of Primary Efficacy Endpoint ................................................. 80 
9.5.4.2 Analysis of Secondary Efficacy Endpoints............................................ 81  
9.5.4.3 Analysis of Exploratory Endpoints ........................................................ 81  
9.5.5 Safety Analyses ..................................................................................................... 81  
9.5.6 PK Analysis .......................................................................................................... 82  
9.5.7 PD Analysis .......................................................................................................... 82  
9.5.8 Biomarker/Pharmacogenetic Analysis .................................................................. 82  
9.5.9 Interim Analysis .................................................................................................... 82  
10 ETHICAL AND LEGAL CONSIDERATIONS .............................................................. 83  
10.1 Compliance with IRB/IEC Regulations ............................................................................ 83  
10.2 Ethical Conduct of the Study ............................................................................................ 83  
10.3 Protection of Hu man Patients ........................................................................................... 83  
10.3.1 Compliance with Informed-Consent Regulations ................................................. 83  
10.3.2 Patient Confidentiality .......................................................................................... 84  
10.3.3 Patient Privacy ...................................................................................................... 84  
11 ADMINISTRATIVE CONSIDERATIONS ..................................................................... 85  
11.1 Study Monitoring ..............................................................................................................  85 
11.2 Quality Management ......................................................................................................... 85 
11.3 Documentation ................................................................................................................. . 86 
11.3.1 Case Report Forms and Study Records ................................................................ 86  
11.3.2 Access to Source Documentation ......................................................................... 86  
11.3.3 Source Documents ................................................................................................ 86  
11.3.4 Study Files and Retenti on of Study Records ........................................................ 86  
11.4 Sample Collection, Prepar ation, and Shipping ................................................................. 87  
11.5  Long-Term Retention of Biological Samples 
................................................................... 87  
11.6 Clinical Supplies ............................................................................................................. .. 88 
11.6.1 Inventory, Reconciliation, Return, and Disposition of Clinical Supplies ............. 88 
11.6.2 Clinical-Supply Inventory ..................................................................................... 88  
11.6.3 Return or Disposal of St udy Drug and/or Supplies .............................................. 88  
11.7 Drug Accountability.......................................................................................................... 88 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 18 of 105 11.8 Post-Trial Care ............................................................................................................... ... 89 
11.9 Protocol Nonc ompliance ................................................................................................... 89  
11.10 Financial Disclosure.......................................................................................................... 89 
11.11 Publication and Disclosure Policy .................................................................................... 89  
12 REFERENCES ................................................................................................................. 91  
APPENDICES .................................................................................................................... .......... 94 
Appendix A: Schedule( s) of Activities .........................................................................................  95 
Appendix B: Summary  of Changes ............................................................................................ 100  
 
LIST OF TABLES 
Table 1  Study Drug and Placebo: Description, Admin istration, Packaging, and Storage ..41  
Table 2  Criteria for Dose Modification or Discontinuation Due to Special Safety Events 44  
Table 3  Permitted Concomitant Medications ......................................................................46  
Table 4  Clinical Laboratory Variables Evaluated During the Study ..................................56  
Table 5  List of Efficacy Assessments .................................................................................57  
Table 6  Time Window for Collection of  2-hour oGTT Blood Samples .............................58  
Table 7  Time Windows for Collection of  Pharmacokine tic Samples .................................61  
Table 8  AE Grades Based on the Common Termi nology Criteria for Adverse Events .....75  
Table 9  Causal Attribution Guidance for AEs ....................................................................76  
Table 10  Definitions of Analysis Populations ......................................................................78  
Table 11  Schedule of Clinical Assessments and Procedures ................................................95  
Table 12  Summary of Changes in Protocol CORT125134-456 Amendment 3 .................101  
LIST OF FIGURES 
Figure 1  CORT125134-456 Study Design ...........................................................................33  
Figure 2  Sequential Gatekeep ing Hierarchy ........................................................................79  
 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 19 of 105 LIST OF ABBREVIATIONS AND DEFINITIONS 
Abbreviation Definition 
ABPM ambulatory blood pressure monitoring 
ACTH adrenocorticotropic hormone 
AE adverse event 
ALT alanine aminotra nsferase (SGPT) 
AST aspartate aminotransferase (SGOT) 
AUC area under the con centration-time curve 
AUC 0‚Äì24h AUC values from time 0 to 24 hours postdose 
AUC glucose  area under the concentration-time curve for glucose  
AUC inf AUC values from time 0 extrapolated to infinity 
AUC last AUC values from time 0 to time of last measurable concentration 
BDI-II Beck Depression Inventory¬Æ-II 
BP blood pressure 
CFR Code of Federal Regulations 
CI confidence interval 
Cmax maximum concentration 
Cmin minimum concentration within a dose interval 
CRF case report form 
CTCAE Common Terminology Criteria for Adverse Events 
CYP cytochrome P450 
DBP diastolic blood pressure 
DHEA-S dehydroepiandrosterone sulfate 
DM diabetes mellitus 
DRB Data Review Board 
DST dexamethasone suppression test 
DXA dual-energy X-ray absorptiometry 
ECG electrocardiogram 
EC Ethics Committee 
EMA European Medicines Agency 
eCRF electronic case report form 
ET early termination 
FDA (United States) Food and Drug Administration 
FKBP5 FK506-binding protein 5 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 20 of 105 Abbreviation Definition 
FU follow-up 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GCP Good Clinical Practice 
GGT gamma-glutamyl transferase 
GLP Good Laboratory Practice 
GMP Good Manufacturing Practice 
GR glucocorticoid receptor 
HbA 1c hemoglobin A1c 
Hgb hemoglobin 
HOMA IR homeostatic-model assessment of insulin resistance 
HPA hypothalamic-pituitary-adrenal 
ICF informed consent form 
IDMC Independent Data Monitoring Committee 
IEC Independent Ethics Committee 
IGT impaired glucose tolerance 
IHC immunohistochemistry 
IND Investigational New Drug  
IRB Institutional Review Board 
ITT intent-to-treat 
Ki inhibition constant 
m-RNA messenger RNA 
MedDRA Medical Dictionary for Regulatory Activities 
mITT modified intent-to-treat 
MR mineralocorticoid receptor 
oGTT oral glucose tolerance test 
PD pharmacodynamic 
PK pharmacokinetic 
PR progesterone receptor 
PTT partial thromboplastin time 
QoL quality-of-life 
QTc corrected QT interval 
QTcF QT interval corrected for heart rate using Fridericia‚Äôs equation: QTcF=QT/(RR—ø) 
REB Research Ethics Board 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 21 of 105 Abbreviation Definition 
SAE serious adverse event 
SBP systolic blood pressure 
SD standard deviation 
SE standard error  
SEM standard error of the mean 
SOA schedule of activities 
SOC system organ class 
t1/2 apparent terminal elimination half-life 
TAT tyrosine aminotransferase; thrombin antithrombin 
TEAE treatment-emergent adverse event 
UFC urinary free cortisol 
ULN upper limit of normal 
US United States 
WBC white blood cell (count) 
 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 22 of 105 1 INTRODUCTION: BACKGROUND INFORMATION AND 
SCIENTIFIC RATIONALE 
1.1 Therapeutic Area 
Hypercortisolism, often referred to as Cushing syndrome, is caused by excessive activity of the 
hormone cortisol. Endogenous Cushing syndrome is a rare endocrine disease associated with 
prolonged exposure to abnormally high levels of cortisol. Clinical manifestations vary, but most 
patients experience one or more of the followi ng: hyperglycemia, hyperte nsion, central obesity, 
facial plethora, abnormal fat dist ribution (supraclavicular fat pads  and ‚Äúbuffalo hump‚Äù), proximal 
muscle weakness, skin thinning, and easy brui sing. Irritability, anxiety, depression, sleep, and 
cognitive disturbances are also common. 
Establishing the diagnosis of Cushing syndrome is  often difficult because few of the symptoms 
or signs are pathognomonic of the syndrome in is olation. There is a large variation in disease 
severity, depending on dura tion and intensity of excess cortis ol production. Furthermore, some 
disease manifestations (e.g., as  hypertension, obesity, and glucos e intolerance) are common in 
individuals who do not have cortisol excess. The diagnosis of Cushing syndrome involves three 
steps: 1) suspecting it based on the patient‚Äôs signs and sympto ms, 2) documenting the presence 
of hypercortisolism, and 3) determining the caus e of hypercortisolism.  
Determination of the cause of hypercor tisolism requires an understanding of the 
pathophysiology of the different types of Cu shing syndrome. Cushing syndrome may be 
either adrenocorticotropic hormone (ACTH) de pendent or ACTH independent. The most 
common cause of overt Cushing syndrome is ACTH-secreting pituitary tumors, followed by cortisol-secreting adrenal tumors or hyperplasia. Ectopic Cushing syndrome, which can produce 
severe manifestations of exce ssive cortisol activity, is a rare form of Cushing syndrome 
secondary to nonpituitary, ACTH-secreting tumors (b enign or malignant). Fo r patients with overt 
endogenous Cushing syndrome, there is consensus about the need for treatment, with surgical 
resection of the ACTH-or cortisol-secreting tumor as the first-line treatment. In cases in which 
surgery has failed, or is not an option, medical th erapy targeting cortisol synthesis or cortisol 
activity is used.  
Management of patients with milder forms of Cushing syndr ome, in particular those with 
cortisol-secreting adrenal adenomas or hyperpl asia, is more challenging. Although these patients 
lack many of the more specific signs of ‚Äòo vert‚Äô Cushing syndrome (Cushingoid appearance, 
proximal muscle weakness, easy bruising, and striae) , they frequently have one or more of the 
less-specific comorbidities associated with elev ated cortisol, includi ng hypertension, diabetes 
mellitus (DM)/impaired glucose tolerance (IGT), central obesity, dyslipid emia and osteoporosis 
(Fassnacht et al. 2016 ).  
Several surgical series in patients with cortisol-secreting adrenal masses have failed to 
consistently demonstrate a causal relationship between hype rcortisolism and comorbidities 
common in the general population (e.g., hype rglycemia, hypertensi on, dyslipidemia, and 
obesity). In some reports, a significant propor tion of patients undergoing surgery experienced 
improvement of cortisol-ex cess-related comorbidities (e.g., hypertension, DM/IGT, obesity) 
(Toniato et al. 2009 , Bancos et al. 2016 ). For example, Toniato, et al reported that post 
adrenalectomy and norma lization of cortisol 
and ACTH levels, appr oximately half of 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 23 of 105 patients experienced normalizati on of obesity, and approximate ly 40% and 80% of patients 
had normalization/imp rovement of hyperglycemia a nd hypertension, respectively ( Toniato et al. 
2009). Similar to Toniato‚Äôs study, several other surgic al series showed that clinical improvement 
is often observed with adrenalectomy, but not in every case ( Fassnacht et al. 2016 ). 
The European Endocrine Society recommends cons idering the risk of malignancy in helping 
determine whether surgery is the proper course for the management of adrenal incidentalomas 
(Fassnacht et al. 2016 ). For patients with bilateral adrenal tumors, unilateral adrenalectomy can 
significantly improve the disease (Bancos et al. 2016 ). However, due to continuous growth of the 
contralateral gland, relapse is  common. Resection of the sec ond adrenal gland, or bilateral 
adrenalectomy as a first-line therapy, is associ ated with primary adrenal insufficiency, which 
requires lifelong treatment with glucocorticoid and mineralocor ticoid analogues and significant 
morbidity.  
If hypercortisolism in the presence of an adrenal adenoma or hyperplasia is suspected, abnormal 
cortisol secretion is demonstrated using th e 1mg overnight dexamethasone suppression test 
(DST). Historically, the cortisol cut-off following the DST to make a diagnosis has been a source 
of debate in the endocrine community. But in 2015, the European endocrine guidelines for 
adrenal incidentalomas agreed to interpret the re sults of this test using a continuous variable 
rather than a categorical one (i.e., usi ng a numerical value instead of Yes/No) ( Fassnacht et al. 
2016). By these guidelines, a value ¬î »ùJG/  (50 nmol/L) is considered ‚Äònormal‚Äô. This cut-off 
value is supported by studies demonstrating that  patients with post-de xamethasone cortisol 
YDOXHV!»ùJG/  have increased morbidity or mortality. For patients with post-DST serum 
cortisol of 1.9‡ØÖ »ùJG/  51‡ØÖ138 nmol/L), and without overt Cushing syndrome, the committee 
proposed the term ‚Äòpossible autonomous cortisol secretion‚Äô. For patients with higher values, the 
term ‚Äòautonomous cortisol secretion‚Äô was proposed ( Fassnacht et al. 2016 ).  
Although surgery is usually recommende d in patients who have a DST >5 »ùJ/dL and the 
presence of 2 or more comorbidities (at leas t one of which is poorly  controlled by medical 
treatment), there remains a lack of consensus on the optimal treatment appr oach (i.e., surgery vs. 
symptomatic treatment of comorbidities) for patients with adrenal adenoma and post-DST serum 
cortisol between 1.9 ‡ØÖ »ùJG/ . 
Although patients with cortisol-secreting adrenal lesions do not ofte n progress into overt Cushing 
syndrome, they may develop comorbidities, including hypertension, DM/IGT, and dyslipidemia, 
and currently it is not possible to predict which patients might bene fit from adrenalectomy 
(Zografos et al. 2014 , Elhassan et al. 2019 , Fassnacht et al. 2016 ).  
Recent retrospective studies have demonstrated  an association between hypercortisolism and 
cardiovascular and bone abnormalities ( Debono et al. 2014 , Debono et al. 2013 ), and it has been 
reported that patients with milder  forms of Cushing syndrome do 
not receive specific treatment 
for their hypercortisolism and instead receive sy mptomatic treatment of  their metabolic and 
cardiovascular symptoms ( Zografos et al. 2014 ). Although there is accumulating evidence to 
support the role of cortisol in the disease profile  of these patients, dire ct management of the 
underlying hypercortisolism is not standard clinical practice ( Fassnacht et al. 2016 , Chiodini et 
al. 2019 , Morelli et al. 2016, Zografos et al. 2014 ). 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 24 of 105 Other treatment options for hype rcortisolism have limitations in the setting of adrenal adenoma 
or hyperplasia. Agents targeting ACTH secr etion (pasireotide) are not beneficial for 
ACTH-independent hypercortisolism. For cortisol-synthesis inhibitors (e.g., ketoconazole, 
metyrapone, and mitotane), the normalization of urinary free cortisol (UFC) is used to monitor 
titration to avoid overtreatment and ensuing adrenal insufficiency. Patients with cortisol-
secreting adrenal adenomas, however, do not us ually present with elevated UFC levels. 
Glucocorticoid receptor (GR) anta gonists, which are titrated via c linical efficacy and tolerability 
and not UFC measurements, could play a useful role in the management  of hypercortisolism due 
to adrenal adenoma/hyperplasia. The concept of  using GR antagonists for the management of 
hypercortisolism due to adrenal ad enoma is similar to the use of  aldosterone-receptor antagonists 
for the treatment of primary aldosteronism. 
Mifepristone, the first GR antagonist to become  available for the treatment of patients with 
Cushing syndrome in the US, was approved followi ng an open-label study de monstrating clinical 
improvement in glucose control. In the pivotal  trial with mifepristone , all patients had overt 
Cushing syndrome; there were no patients with benign adrenal tumors. Ca se reports and small 
case series in patients with autonomous cortisol secretion treated with mif epristone demonstrated 
improvement in hyperglycemia  and weight loss similar to the surgical series (Belokovskaya et al. 
2019, Debono et al. 2013). However, a smaller effect on hypertension was seen. The lack of as 
strong an effect on hypertension is likely due to  the significant increase in ACTH levels 
following treatment with mifepristone, which stimulates secretion of additional cortisol from the 
adrenal adenoma and normal cortisol-secreting cel ls of the adrenal cortex, which, in turn, 
stimulates the mineralocorticoid receptor (MR).  
Relacorilant (CORT125134) is a next-generation GR antagoni st being developed for the 
treatment of Cushing syndrome and other conditions that was designed to overcome adverse 
effects of mifepristone. 
1.2 Relacorilant 
Relacorilant is a selective, hi gh-affinity antagonist of the GR (inhibition constant <1 nM in a 
human GR binding assay and <10 nM in a human  functional assay) a nd it has considerably 
greater selectivity for GR over the progesterone receptor (PR), producing only 7% displacement 
of labelled progesterone at a concentration of 1 ¬óM (relacorilant K i >10 ¬óM, mifepristone 
Ki=1.2 nM) in a PR ligand binding assay (Cerep Report 100011862).  Given this selective and 
potent GR antagonism, relacorilant has the poten tial advantage compared with mifepristone of 
not having any antiprogesterone effects, including endometrial hypertrophy and the potential for 
irregular vaginal bleeding. The effect of relacorila nt on the pituitary also appears to be smaller 
compared with mifepristone‚ÄîACTH levels appear to be less affected in both patients with 
ACTH-dependent and adrenal Cushing syndrome ( CSR CORT125134-451 ), which offers a 
potential advantage of relacorilant over mifepristone in the treatment of patients with 
hypercortisolism due to adrena l adenoma or hyperplasia.  
1.3 Clinical Summary 
A brief summary of relacorilant clinical studies is presented (Sections  1.3.1 and 1.3.2). Further 
details on pharmacology, absorption, distributi on, metabolism, and elimination (ADME), and 
toxicology of relacorilant are presente d in the Investigator‚Äôs Brochure.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 25 of 105 1.3.1 Phase 1 Studies 
In a single-ascending dose/multiple-a scending dose study (Study CORT125134-120; 
[STUDY_ID_REMOVED]), 84 healthy subjects received single dos es of up to 500 mg or repeated doses of 
up to 250 mg daily of the ‚Äòclinical-pharmacology‚Äô  formulation (an earlier formulation with a 
higher bioavailability than the current ‚Äòclinical-tri al formulation‚Äô). In th is study, a single dose of 
500 mg or multiple doses of 250 mg of relacor ilant along with a high dose of prednisone in 
healthy subjects showed prevention of the cha nges induced by prednisone alone in several 
glucocorticoid-induced biomarke rs, including osteocalcin, lym phocytes, eosinophils, and FKBP5 
mRNA levels. Single doses of relacorilant up to  500 mg daily were well tolerated. During the 
repeated-dose parts of Study CORT125134-120, there was a dose-related trend in subjects who 
reported at least 1 treatment-emergent advers e event (TEAE): 44.4% (50 mg), 66.7% (150 mg), 
and 85.7% (250 mg), compared with 50% of pl acebo-treated subjects. The most commonly 
reported TEAEs were within the system orga n class (SOC) musculos keletal and connective 
tissue disorders.  
Two additional studies in healthy vol unteers (Study CORT125134-453, Study CORT125134-
126), with multiple doses of relacorilant have been completed. In Study CORT125134-453, in 
which multiple doses of 150 mg, 250 mg, and 350 mg relacorilant daily, the most commonly 
reported TEAEs were musculoskele tal, connective tissue, GI, a nd nervous system related. The 
most commonly reported TEAE were headache, for which a dose-related trend was reported 
(12.5%, 25.0%, and 37.5% of subjects followi ng dosing with 150 mg, 250 mg, and 350 mg 
relacorilant daily, respectively) , and back pain, which was reported at the 350 mg dose level 
only, in 50% of subjects. Similar safety results were observed in Study CORT125134-126. 
In the drug-drug interaction Study CORT125134-126, rel acorilant exhibited no relevant effect on 
exposure to probe substrates for CYP2D 6, CYP2C8, CYP2C9, or CYP2C19. However, 
relacorilant was shown to be a strong CYP3A inhibitor of the probe substrate midazolam, 
resulting in AUC extrapolated to infinity (AUC inf) and C max of 8.8-fold and 3.3-fold higher, 
respectively, relative to midazolam alone.  
Study CORT125134-129 was conducted w ith relacorilant 400 mg (4 √ó 100 mg  capsule; 
clinical-trial formulation that is also consid ered the ‚Äúto-be-marketed‚Äù formulation). Following 
administration of relacorilant  under fed conditions with a lo w-fat meal, relacorilant C max and 
AUC inf increased approximately 69% and 2.0-fold , respectively, relative to relacorilant 
administered under fasting conditions. Following administration of relacorilant under fed 
conditions with a high-fat meal, relacorilant C max and AUC inf increased approximately 92% and 
2.4-fold, respectively, relative to relacor ilant administered under fasting conditions. 
1.3.2 Phase 2 Study 
A total of 35 patients were incl uded in the Safety Population of this Phase 2, open-label, 
multicenter, dose-escalation study in patients with endogenous Cushing syndrome (Study 
CORT125134-451; [STUDY_ID_REMOVED]). Group 1 (n=17) had a two-step dose escalation (monthly) of once-daily relacorilant (dose range, 100‚Äì200 mg, c linical-trial formula tion; total treatment 
period, 12 weeks), and Group 2 (n=18) had a three- step dose escalation (monthly) of once-daily 
relacorilant (dose range, 250‚Äì400 mg, clinical-t rial formulation; to tal treatment period, 

Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 26 of 105 16 weeks). Relacorilant exposur e remained well below the 40 ¬óg‚Ä¢h/mL cap (exposure limit 
guided by results of the toxico logy studies) at all doses.  
Overall, 94.3% of patients experienced TEAEs . In Group 1, 15/17 (88.2%) patients experienced 
a total of 101 TEAEs. The most common ¬ï TEAEs in Group 1 were back pain, diarrhea, 
headache, and pain in extremity (23.5% each).  In Group 2, all 18 patients (100%) experienced a 
total of 228 TEAEs. The most common ¬ï TEAEs in Group 2 were back pain (38.9%), 
headache and nausea (27.8% each), and abdomin al pain, arthralgia, dizziness, dyspepsia, 
myalgia, and pain in extremity (22.2% each).  
There were no TEAEs resulting in death during the study. Four (11.4%) patients experienced 
treatment-emergent SAEs (TESAE s); no TESAEs were reported in Group 1 and 5 TESAEs (in 
4 patients) were reported in Group 2. All TES AEs were Grade 3 in severity. Three (8.6%) 
patients had TESAEs (polyneuropat hy, myopathy, and acute myocardial infarction) that were 
considered possibly related to study drug by the Investigator and led to study-drug 
discontinuation. These TESAEs were considered not related to the study drug by the Sponsor.  
Because relacorilant affects cortis ol action and not cortisol secretion, measuring cortisol levels is 
not a suitable method to monitor the treatment effect . Therefore, the efficacy of relacorilant in 
this study was measured based on improvement of cortisol-excess-related comorbidities (e.g., 
hyperglycemia and hypertension).  
For patients with DM at Baseline DGHFUHDVHLQ+E$FE\¬ïIURP %DVHOLQH WR WKH ODVW YLVLW
normalization of the 2- KRXUR*77JOXFRVH  PJG/G HFUHDVHE\¬ï PJG/IURP%DVHOLQH
WRODVWYLVLWRUGHFUHDVHLQW RWDO GDLO\ LQVXOLQ GRVHE\ ¬ï ZLWK+E$FXQFKDQJHGRU
decreased compared with Baselin e) was considered a clinica lly meaningful response. For 
patients with IGT at Baseline, normalization of the 2-hour oG TT glucose was considered a 
response. In the mPP Population (IGT/diabetes subgroup), 2 of 13 (15.38%) patients (95% CI 
lower bound 1.92%) in Group 1 and 6 of 12 (50%) patients (95% CI lower bound 21.09%) in 
Group 2 met at least one of the above response criteria. 
For patients with uncontrolle d hypertension at Baseline DGHFUHDVHRI¬ïPP+JGHFUHDVHLQ
mean systolic BP (SBP) and/or di astolic BP (DBP) from Baseline to  last visit, without worsening 
of either, based on 24-hour ambulatory BP monitoring (ABPM), was considered a response. 
Among patients with hypertension, 41.7% of patie nts in Group 1, and 63.6% of patients in 
Group 2 responded.  
In summary, this Phase 2 study of relacorila nt (Study CORT125134-451), de monstrated clinical 
improvement in glucose control and in hypertension in patients with Cushing syndrome. There 
was also improvement in several comorbidities associated with cortisol excess, including 
improvement in quality of lif e and other comorbidities incl uding CNS manifestations (e.g., 
depression and cognitive impairm ent), bone metabolism, coagul ation parameters, and liver 
function tests. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 27 of 105 1.4 Rationale for Study Design and Dose Regimen  
1.4.1 Design Considerations 
This will be a Phase 3, randomized, double-blind, placebo-controlled study conducted in the US, 
Europe, and Israel at approxima tely 60 sites. Approximately 130 patients will be randomized 1:1 
to relacorilant or placebo.  
The study proposed here specifically targets pa tients with hypercortiso lism due to cortisol-
secreting adrenal adenomas or hyperplasia. Thes e patients may or may not present the classic 
clinical manifestations of overt  Cushing syndrome (i.e., facial appearance, buffalo hump, striae, 
etc.). Although adrenal tumors are frequently detected incidentally during abdominal imaging 
studies (incidentalomas), especially in older patie nts, up to 29% of these tumors secrete cortisol 
(Fassnacht et al. 2016 ).  
Because of the mechanism of action of relacorilant , a GR antagonist that doe s not affect cortisol 
levels, efficacy will be assessed by monitoring clinical manifestations frequently associated with 
cortisol excess‚Äîhyperglycemia (DM/IGT) and h ypertension. Two robust and validated clinical 
measures of blood glucose control and blood pressu re (BP) control, will be used. For patients 
with hyperglycemia, glucose metabo lism and insulin resistance will be evaluated with the oGTT. 
The secondary endpoint of the mean change in the AUC glucose  was chosen because it reflects 
glucose control in patients with diabetes as well as those with IGT, for whom neither HbA1c nor 
fasting glucose are reliable m easures of glucose control. The primary endpoint of mean  change 
in SBP was chosen because adrenal adenomas ar e usually diagnosed in older patients for whom 
systolic hypertension is most frequently observe d (diastolic hypertension is more frequently 
observed in younger patients). This endpoint uses 24-hour ambulatory blood pressure monitoring (ABPM), which is considered th e gold-standard measurement.  
To examine the many manifestations of cortis ol excess in the study patients, several other 
efficacy assessments will be used to assess clinical benefit, including assessment of Quality-of-Life, bone microarchitecture, weight, whole- body fat composition, coagulation markers, and 
lipid profile.  
1.4.2 Rationale for Dose Selection and Regimen 
Dose selection for this study was based on PK and safety results fr om Phase 1 studies in healthy 
subjects and safety, efficacy, and PK results in a Phase 2 study in patients with Cushing 
syndrome (CORT125134-451) (see Section  1.3.2). Across all studies, expos ure to relacorilant (as 
AUC
0-24h) at steady-state was well below the toxico logy threshold and was consistent between 
healthy subjects and patients with Cushing syndr ome. The PK of relacorilant support once-daily 
dosing. 
In the Phase 2, open-label, multicenter Study CORT125134-451, 35 patie nts with endogenous 
Cushing syndrome received daily relacorila nt in escalating doses ranging from 100 ‡ØÖ200 mg 
(Group 1, 12 weeks) or from 250 ‡ØÖ400 mg (Group 2, 16 weeks).  
Efficacy results indicate that treatment with relaco rilant in patients w ith endogenous Cushing 
syndrome leads to improved glycemic and hyp ertension control. In Group 1, clinically 
significant changes in DM/IGT and hypertension c ontrol were generally observed starting with 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 28 of 105 the 200-mg dose. In Group 2, most responders start achieving clinical benefit at the starting dose 
of 250 mg daily, although some pa tients required doses up to 400 mg  daily for optimal benefit.  
There was, however, a difference in the TEAEs  between the two groups. In Group 1, treatment 
was generally well tolerate d. In Group 2, patients experienced TEAEs (especially 
musculoskeletal symptoms) at a higher frequency and with greater intensity compared with patients in Group 1. Although the maximum dose of relacorilant in Group 1 (200 mg) was very 
well tolerated, every patient in Gr oup 2 experienced TEAEs at the starting dose of relacorilant of 
250 mg daily, despite the fact that the levels of relacorilant at the highest dose of Group 1 (i.e., 
200 mg) were similar to the levels achieved with the starting dose of relacorilant in Group 2 (250 mg). The frequency of TEAEs in Group 2 decreased with continuous therapy with 
relacorilant at the same or highe r dose indicating that most of t hose TEAEs were consistent with 
cortisol-withdrawal symptoms, commonly seen in  patients starting on an effective dose of a 
Cushing syndrome medication without preceding titr ation. Therefore, the approach in this study 
is to titrate the relacorilant dose from a starting dose of 100 mg, which wa s well tolerated in the 
Phase 2 study, to higher potentially more efficacious doses. 
1.5 Risk/Benefit Assessment 
The United States (US) Food and Drug Administration (FDA), as well as the European 
Medicines Agency (EMA), acknowledge the impact of coronavirus disease 2019 (COVID-19) on 
the health system and broader society, and rec ognize the impact it could ha ve on trials and trial 
participants ( FDA 2021 , EMA 2022 ). Both agencies underscore that safety of trial participants is 
paramount.  
In addition to the risks/potential benefits to trial par ticipation, the added ch allenges of conducting 
a clinical trial during the time of the public health emergency related to COVID-19 require the 
Sponsor to perform initial and ongoing risk asse ssment to determine its potential impact on the 
safety and confidentiality/privacy of the trial participant, integrity of the trial, and the benefit of 
the trial for participants and society. 
With regard to Protocol CORT 125134-456, Corcept has been working with clinical investigators 
and Institutional Review Boards (IRBs)/Ethics Committees (Ecs) on a continuing basis to ensure 
that the patient‚Äôs safety, welfare, and rights are be st served by participating in this trial. Corcept 
will continue to communicate guidance and provi de support to clinical study sites during the 
COVID-19 pandemic. 
x Corcept recognizes that the protocol may requi re modification to ensure integrity of the 
trial and appropriate safety monitoring are implemented for all enrolled trial participants. 
This may involve alternative methods for safety and study assessments (i.e., phone contact, virtual study visits, use of alternative locations for assessment, including local labs or imaging centers, etc.). New processes or modifying protocol -described processes 
may be required, depending on the specific situation.  
x Corcept also recognizes that, depending on th e specific situation, treatment with the 
investigational pr oduct may be ended or paused.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 29 of 105 x Lastly, Corcept recognizes that if the st udy cannot be properly conducted under the 
existing protocol, it could be necessary to amend the protocol, stop recruitment, and/or 
withdraw trial participants. 
All decisions will be properly doc umented. Risk assessment will be  made on an ongoing basis.  
As required, information pertaining to protocol modifications (including study visits, remote 
study monitoring, investigational drug supply distri bution, etc.) as a result of COVID-19 will be 
recorded and submitted to Regulatory Agencies and/or IRBs/Ecs in accordance with COVID-19 
guidances issued at country level and/or by IRB/EC, unless otherwis e requested/required by 
these entities. 
As described in the EMA guideline, ‚ÄúIt is expect ed that the sponsor performs a risk assessment  
of each individual ongoing trial and the investigator of each individual trial participant and 
implement measures, which prioritize trial participant safety and data validity. In case these two 
conflict, trial participant safety always prevails. ‚Äù 
The following risk assessments and aspects of trial conduct will be considered by Corcept on an 
ongoing basis in conjunction with clin ical investigators and IRBs/IECs, as applicable, to ensure 
that the safety of trial participants can be maintained:  
x Whether the limitations imposed by the COVID- 19 public health emergency on protocol 
implementation pose new safety risks to trial participants, and whether it is feasible to 
mitigate these risks by amending study processes and/or procedures. 
x Whether there will be continued availability of the clinical investigator/sub-investigators to provide oversight of the tr ial, and properly assess and manage safety issues that 
may emerge. 
x Whether there will be suff icient trial support staff given the evolving COVID-19 
situation, and that staff are appropriately trained and coul d be available to handle the 
expected tasks, and that they have adequate equipment and materials. 
x Whether clinical investigator sites will remain open to trial participants for required 
in-person assessments or whether the clinical investigator has the ability to provide 
required in-person assessments at an acceptable alternate location(s), or whether such protocol-specified in-per son assessments can instea d be conducted virtually. 
x Whether there is continued supply of the i nvestigational product a nd/or trial supplies 
essential to maintaining appropriate safety monitoring or other key trial procedures for 
trial participants. 
x Whether there is continued availability of, and support for, information technology systems and any other technological tools needed to support the trial. 
x Whether there will be continued operations of, and adequate communications with, IRB/EC, if applicable, to support trial needs. 
x Whether it is feasible to conduct the tria l in light of any COVID-19 public health 
measures implemented by Federal/Government, state, and/or local authorities to control the virus. 
 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 30 of 105 Depending on the specific situa tion, additional assessments may be added. Study participants 
will be informed of changes to the study and monitoring plans that could affect them. Processes 
for remote monitoring will include the protection of trial participant data privacy and confidentiality. Study partic ipants may choose not to participat e in this study or may leave this 
study at any time, without having to give a reason.  Study participants will still receive care for 
their condition and will not be penalized or lose any benefits to which they are otherwise entitled. They will not lose any rights they are entitled to as a study participant. 
Patients with endogenous Cushing syndrome ar e immunocompromised due to a direct 
suppressive effect of high cortisol on the bone marrow and immune cells, as well as due to an 
effect on the immune system of the cortisol-H[FHVV‡ØÖUHODWHGFRPRUELGLWLHVHJGL abetes, 
hypertension, obesity). Patients with Cushing synd rome who remain untreated are at high risk 
for infections from common and uncommon pat hogens. Infection is the second most common 
cause of death among patients with overt Cushing syndrome ( Dekkers et al. 2013 ) and in 
patients with milder forms of hypercortisolism due to cortisol -secreting adrenal adenomas 
(Debono et al. 2014 ). In Study CORT125134-451, in which patients with endogenous Cushing 
syndrome were treated with relacorilant, in the high-dose group, we observed an overall increase in the number of lymphocytes (which is of ten suppressed in this patient population).  
In addition, should a patient in the study become  infected with COVID-19, the Investigator 
should consult the Medical Monitor regarding any possible interactions of relacorilant with the various treatment options for COVID-19. 
COVID-19 measures cited in this protocol am endment are temporary and will be repealed 
back to previous state when the situation (governmental rules, benefit/r isk assessment for the 
trial) allows. Glucocorticoid receptor antagonism is a proven mechanism of action for the treatment of the 
DM/IGT secondary to hypercortisolism in adult patients with Cushing syndrome ( Fleseriu et al. 
2012). Relacorilant antagonizes the GR similar to mifepristone, but has no effect on the PR. Relacorilant is therefore expected to effectivel y treat hypercortisolism, without the drawbacks of 
PR antagonism that may result in untoward reprod uctive effects, which may lead to interruption 
of therapy. 
In the Phase 2 study (Study CORT125134-451) in patients with endogenou s Cushing syndrome, 
relacorilant showed evidence of clinical benefit based on improve ment of cortisol- H[FHVV‡ØÖUHODWHG
comorbidities. The drug was well tolerated, with the most common side effects observed at 
higher doses. Compared with the predecessor dr ug mifepristone, relacorilant offers two key 
safety advantages‚Äîlack of affinity for the PR, an d lack of significant cor tisol rise (which is 
mostly responsible for the hypokalemia a nd worsening hypertension observed with 
mifepristone).  
Based on the mechanism of action of relacorilant, there is a theoretical risk of excessive 
GR antagonism, which could manifest by weakness, tiredness, dizziness,  nausea, vomiting, and 
muscle aches. Since relacorilant does not aff ect the MR, it is unlikely that hypotension would 
occur in the absence of antihypertensive medicat ion. Because plasma gluc ocorticoid levels are 
not decreased with relacorila nt administration, a single labor atory test of excessive GR 
antagonism is not possible; diagnosis must rely on clinical assessment. In cases of suspected 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 31 of 105 excess GR antagonism, study drug will be in terrupted for 3 days and supplemental 
glucocorticoid may be given to overcome the GR antagonism (see Section  5.4.1).  
The safety profile of relacor ilant in study patients will be m onitored by physical examinations, 
measurement of vital signs, blood tests for analysis of clinical chemistry and hematology 
parameters, 12-lead electrocardiograms (ECGs), and AEs.  
Patients receiving placebo cannot expect a meani ngful improvement of th e manifestations of 
their hypercortisolism. However, these tumors pr ogress very slowly, and rarely progress into 
overt Cushing syndrome (Fassnacht et al. 2016 ). Thus, no significant worsening of the clinical 
manifestations of hypercortis olism is expected in the placebo group during the study.  
Relacorilant is metabolized by multiple CYP enzymes, including CYP3A and CYP2C8, and by 
carbonyl reductases. Relacorilant is a strong inhibitor of CYP3A. If a concomitant medication is 
required to treat an AE, the Investigator must consider the risk of drug-drug interaction. 
Study procedures include venous blood sampli ng and noninvasive procedures, including ECG 
recording, imaging, and vital-sign measurement. During cannulation, more than 1 attempt may 
be needed to insert the cannula in a vein of a patient, and it is possible that bruising and/or 
inflammation may be experienced at the site of cannulation. Because dual-energy X-ray absorptiometry (DXA) scans use X-ray energy, there is risk due to exposure radiation. The total 
volume of blood collected will not exceed 505 mL, unless the Investigator or designee considers 
additional unplanned collecti on(s) are required for safety laboratory tests.  
Because the study is placebo cont rolled, measures are in place ( Section  5.5) to allow patients to 
receive treatment for comorbid conditions as necessary.  
More information on the risks and benefits of relacor ilant is provided in the Investigator‚Äôs 
Brochure. 
 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 32 of 105 2 STUDY OBJECTIVES 
2.1 Primary Objectives 
x To assess the efficacy of relacorilant for the treatment of hyperc ortisolism in patients 
with cortisol-secreting adrenal adenomas or  hyperplasia, based on blood pressure (BP) 
control at Week 22 compared with placebo 
x To assess the safety of relacorilant for the treatment of hypercortisolism  
2.2 Secondary Objective 
x To assess changes in cortisol excess -related comorbidities (e.g., body weight and 
glycemic control) in patien ts with hypercortisolism due to  cortisol-secreting adrenal 
adenomas/hyperplasia 
2.3 Exploratory Objectives 
x To explore changes in cortisol excess-related comorbidities including assessments of 
glucose, insulin resistance indices, coagulation markers, GR activity biomarkers, HPA 
axis, and bone turnover markers, depression a nd quality of life questi onaries in patients 
with cortisol-secreting adrenal adenomas or hyperplasia 
x To assess the pharmacokinetics of  relacorilant in patients with hypercortisolism due to 
cortisol-secreting adrenal adenomas/hyperplasia 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 33 of 105 3 STUDY DESIGN 
3.1 Overall Design 
This is a Phase 3, double-blind, placebo-controlled study to assess the effi cacy, and safety of 
relacorilant to treat hypercortis olism in patients with cortisol-secreting adrenal adenoma or 
hyperplasia associated with DM/IGT and/ or uncontrolled syst olic hypertension. Two 
subgroups‚ÄîDM/IGT and hypertension‚Äîwill be analyzed.  
Figure 1 CORT125134-456 Study Design 
 
3.2 Study Endpoints 
3.2.1 Primary Endpoints  
In patients with systolic hypertension , the mean change in 24-hour average SBP based on 
24-hour ABPM, from Baseline to Week 22 as compared  between relacorilant and placebo arms.  
In all patients , assessment of safety based on TEAEs. 
3.2.2 Secondary Endpoints (from Baseline to Week 22/ET, compared between 
relacorilant and placebo) 
Endpoints for Hypertension 
1. In patients with systolic hypertension at Base line, mean change in average DBP and HR 
(based on 24-hour ABPM). 
2. In patients with systolic hypertension at Base line, mean change in daytime average SBP, 
DBP, and HR (based on 24-hour  ABPM). 
3. In patients with systolic hypertension at Ba seline, mean change in nighttime average 
SBP, DBP, and HR (based on 24-hour ABPM). 
4. In patients with systolic hypertension at Ba seline, proportion of pa tients with any dose 
increase in antihypertensive medicati ons due to worsening hypertension. 
5. In patients with systolic hypertension at Ba seline, proportion of patients with a reduction 
in 24-hour average SBP by 5 mm Hg (based on 24-hour ABPM). 
6. In patients with systolic hypertension at Ba seline, proportion of pa tients with any dose 
decrease in antihypertensive medica tion due to improved blood pressure. 

Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 34 of 105 7. In patients with systolic hypertension at  Baseline, proportion of patients with 
normalization of the average SBP (<130 mm Hg, based on 24-hour ABPM).  
Endpoints for Hyperglycemia 
1. In patients with DM/IGT at Baseline, the mean change in AUC glucose , from Baseline to 
Week 22 as compared between relacorilant and placebo arms. 
2. In patients with DM (HbA1c at Baselin H¬ï WKHPHDQFKDQJHLQ+E$F  
3. ,QSDWLHQWVZLWK'0,*7 +E$F DW%DVHOLQH¬ïWKHPHDQ FKD QJHLQ+E$F  
4. 3URSRUWLRQ RI SDWLHQWV ZLWK+E$F¬ï% at Baseline who achieved HbA1c <6.5%. 
5. In patients with DM at Baseline, propor tion of patients who achieved 2-hour oGTT 
glucose <140 mg/dL. 
6. In patients with IGT at Baseline, propor tion of patients who achieved 2-hour oGTT 
glucose <140 mg/dL. 
7. In patients with DM/IGT at Baseline, propor tion of patients with any dose decrease of 
diabetes medication due to improved glucose control. 
8. In patients with DM/IGT at Baseline, propor tion of patients with any dose increase of 
diabetes medications due to worsening hyperglycemia. 
9. In patients with DM/IGT in the ITT population, the proportion of patients who achieved 
decrease of AUC glucose  RI¬ï¬ï¬ïDQG DQ\GHFUHDVH from Baseline to Week 22. 
10. In patients with DM/IGT in the ITT popula tion, the mean change in 2-hour oGTT 2-hour 
timepoint  from Baseline to Week 22. 
11. In patients with DM/IGT in the ITT popul ation, the mean change in 2-hour oGTT 
predrink timepoint  from Baseline to Week 22. 
Other Secondary Endpoint 
1. In all patients, the mean change in  body weight and waist circumference. 
3.2.3 Exploratory Efficacy Endpoints 
The mean change from Baseline to Week 22/ET in serum osteocalcin; in trabecular bone 
score, bone mineral density, and body compos ition from DXA scans; the Beck Depression 
Inventory¬Æ-II (BDI-II) score; sit-to-stand test score; trail making test scores; coagulation 
markers (Factor VIII, von Willebrand factor, prot ein S, protein C, TAT, platelets, and PTT); 
biomarkers related to GR activity (such as FKBP5); DHEA-S concentrations; ACTH 
concentrations; lipids (total cholesterol, LDL cholesterol, triglycerides, and very-low-density lipoprotein cholesterol); HPA-axis ; difference between morning and late-night salivary cortisol; 
AUC
glucose ; fasting glucose in patients with DM; insulin resistance indices and 
hyperglucagonemia (AUC insulin, Matsuda Index, home ostatic model assessment of insulin 
resistance [HOMA IR], and at selected visits AUC glucagon ), and Cushing Quality-of-Life (Cushing 
QoL) score.  
Intensive pharmacokinetic blood sampling will be conducted in all patients at the Week 18 visit. The plasma concentrations of relacorilant and/or its metabolites will be examined.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 35 of 105 3.3 Number of Patients and Study Duration 
3.3.1 Number of Patients 
Approximately 130 patient s will be randomized. 
3.3.2 Study Duration 
The maximum expected duration of  a patient‚Äôs participation is 32 weeks, including up to 6 weeks 
for Screening, 22 weeks of double-blind treatment, and a follow-up visit 28 days after the last 
dose of study drug. 
3.3.3 Discontinuation of Study Sites 
Participation of a study site may be discontinued if the Spons or, its designee, the Investigator, 
or the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) determines it 
necessary for medical, safety, regulatory, or other reasons consistent w ith applicable laws, 
regulations, and guidelines. 
3.4 Definitions 
3.4.1 Enrollment 
Patients are considered enrolled in the study when they have signed the ICF, been screened, and 
their eligibility has been verified.  
3.4.2 End of Treatment 
The end of treatment is defined as the date on whic h the patient received hi s or her last treatment, 
which may be the end of the Trea tment Period if the patient completed all treatments or may be 
earlier if the patient discontinued study treatment before the designated stopping point at 
Week 22. 
3.4.3 Patient Study Completion 
Patients who complete 22 weeks of the double-bli nd, placebo-controlled phase and return for the 
follow-up visit 28 days after the last dose of study drug will be considered to have completed the 
study. The follow-up visit will serve as the last study visit. 
Patients who complete 22 weeks of the double-b lind, placebo-controlled phase, and enter an 
extension study without interruption will also be considered to have completed the study; in that 
case the follow-up visit will not be required, and Week 22 will serve as the last study visit.  
3.4.4 End of Study 
The end of study is defined as the date of last  contact (visit, telephone, e-mail) with the last 
patient in the study. The Sponsor will ensure that the Institutional Review Board (IRB)/ 
Independent Ethics Committee (IEC) and the regulatory authority(ies) are notified that the study has finished according to Corcept‚Äôs standard operating procedures and/or local or national regulations. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 36 of 105 3.5 Treatment Continuation 
Patients who complete the study w ill be permitted to continue re lacorilant treatment in an 
extension study provided that they have at le ast 80% adherence with  scheduled dosing (by 
capsule counts). Patients who continue on to the extension st udy within 28 days of the last dose 
of study drug will not be required to complete the follow-up visit. The last study visit for these 
patients will be the Week 22 visit.  
Patients who complete the Week 22  visit and do not wish to ente r an extension safety study will 
be instructed to discontinue study drug. Patients should not disc ontinue study drug before all 
the Week 22 assessments are performed and the unblinded medical monitors confirm all the 
data required for the analysis of the primary endpoint have been collected and reported. The 
follow-up visit will be c onducted 28 days after the last dose of study drug and will serve as the 
last study visit. 
3.6 Study Termination by Sponsor 
If the Sponsor/CRO, Investigator, Study Monitor,  or regulatory officials discover conditions 
arising during the study that indi cate that the study should be halted or that the study site‚Äôs 
participation should be terminated, this action may be taken after appr opriate consultation 
between the Sponsor and Investigator. Conditions  that may warrant termination of the study 
include, but are not limited to, the following: 
x Discovery of an unexpected, serious, or unacceptable risk to the patients enrolled in the 
study. 
x Decision on the part of the Sponsor to susp end or discontinue testing, evaluation, or 
development of the product. 
Study termination (if required) a nd follow-up will be performed in compliance with applicable 
regulations and guidelines. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 37 of 105 4 STUDY POPULATION 
This study includes patients with cortisol-secreting adrenal adenom as or hyperplasia associated 
with DM/IGT and/or uncontro lled systolic hypertension.  
The following eligibility criteria are designed to select patients for whom treatment with 
relacorilant is considered a ppropriate. All re levant medical and nonmed ical conditions will be 
taken into consideration when deciding whether treatment with relacorilant is suitable for a 
particular patient.  
4.1 Inclusion Criteria 
Each patient must meet all of the following criteria to be enrolled in the study: 
1. Male or female, 18 to 80 years of age, inclusive. 
2. Lack of cortisol suppression (>1.8 »ùJG/ VHUXP FRUWLVRO ZLW KDGHTXDWHGH[DPHWKDVRQH
levels) on either 1-mg overnight or  2-mg 48-hour DST during Screening. 
3. Suppressed or low ( ¬î15 pg/mL) early-morning ACTH levels on at least 2 occasions 
during Screening. 
4. A radiologically confirmed benign adrenal lesion (single adenoma, multiple adenomas, 
hyperplasia [¬ï 3 times the size of the normal adrenal gland]) within 3 years prior to 
Screening. 
5. Has at least 1 of the following at Baseline: 
 DM (fasting plasma glucose t126 mg/dL and/or 2-hour oGTT plasma glucose 
t200 mg/dL at 2 hours, RU+E$F¬ïRU ,*7 SODVPDJOXFRVH¬ï  mg/dL and 
<200 mg/dL on a 2-hour oGTT) ( American Diabetes Association 2020). 
 Systolic hypertension (average 6%3 ¬ï 0 WR ¬î  mm Hg) based on 24-hour ABPM 
(Parati et al. 2014 ). 
6. If receiving medical treatment for DM/IGT or hypertension, there has been no increase in 
medication dosage for at least 4 weeks prior to Baseline assessment. 
7. For women of childbearing potential, has a ne gative serum pregnanc y test at Screening 
and negative urine pregna ncy test at Baseline. 
4.2 Exclusion Criteria 
Patients who meet any of the following criteri a will not be permitted entry to the study: 
1. Has severe, uncontrolled hypertension (average SBP >170 mm Hg or average DBP >110 mm Hg at Screening), based on 24-hour ABPM. 
2. Has poorly controlled DM (HbA 1c >12% at Screening). 
3. Has DM Type 1. 
4. Has abnormal liver test results (total bilirubin >1.5√óULN or elevated alanine 
aminotransferase or aspartate aminotransferase  >3
 √óULN at Baseline). 
5. +DV VHYHUHUHQDO LQVXIILFLHQF\ JORPHUXODUILOWUDWLRQ UDWH¬î  mL/min/1.73 m2 at 
Baseline). 
6. Has uncontrolled, clinically significan t hypothyroidism or hyperthyroidism. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 38 of 105 7. Has prolonged QT interval corrected for hear t rate using Fridericia‚Äôs equation (QTcF) 
(>450 ms for men and >470 ms for women) w ith normal QRS interval (<120 ms) or 
QTcF interval >500 ms with wide QRS interval ( t120 ms). 
8. Has persistent atrial fibrillation. 
9. Has used or plans to use any treatment s for Cushing syndrome within 12 weeks 
prior to Screening and throughout the study, including mifepristone, metyrapone, 
osilodrostat, ketoconazole, fluconazole, or  any investigational drug for treatment 
of Cushing syndrome. 
10. Patients who require inhaled glucocorticoids and have no alternative option if their 
condition deteriorates during the study. 
11. Has adrenocortical carcinoma.  
12. Has pseudo-Cushing syndrome. Patients with known or suspected pseudo-Cushing syndrome based on medical history (such as  patients with seve re obesity, major 
depression, or a history of alcoholism)  should undergo a dexamethasone-CRH/DDAVP 
stimulation test ( Yanovski et al.1993 , Giraldi et al. 2007 , Yanovski et al. 1998 ) to rule-in 
or rule-out this possibility. 
13. Has a history of cyclic Cushing syndrome w ith fluctuating clinical manifestations. 
14. Has autonomous cosecretion of aldosterone. 
15. Has plans for adrenalectomy or nodulect omy during the study, including follow-up. 
16. Has taken any non-Cushing syndrome investigational drug within 4 weeks prior to Baseline, or within less than 5 times the drug‚Äôs half-life, whichever is longer. 
17. Ongoing use of antidiabetic, antihypertensive, antidepressant or lipid-lowering medications that are highly dependent on CYP3A for clearance and that cannot undergo 
dose modification upon coadministration with strong CYP3A inhibitors.  
18. Ongoing use of any strong CYP3A4 inducer or any other prohibited medications (see Section  5.6). 
19. Is pregnant or lactating. 
20. Is a female patient of childbearing potentia l who cannot use a highly effective method of 
contraception (including all women <50 years old, women whose surgical sterilization 
was performed <6 months ago, and women who have had a mens trual period in the last 2 
years); see Section  4.6.2.  
21. Has an acute or unstable medical  problem that could be aggravated by treatment with the 
investigational study drug. 
22. Has a history of severe re
 action to the st udy drug, to a similar class of drug, or to the 
study drug‚Äôs excipient. 
23. In the Investigator‚Äôs opinion, should not partic ipate in the study or may not be capable of 
following the study schedule. 
24. Has known HIV, hepatitis B, or hepatitis C infection a nd is taking medication for 
treatment of HIV, hepatitis B, or hepatitis C infection. 
25. Has used mitotane prior to Baseline. 
4.3 Screen Failures 
Screen failures are defined as patients who consent to participate in the clinical study but did not 
meet the eligibility criteria for the study and were not enrolled.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 39 of 105 Patients who fail screening due to a laboratory result may be retest ed within the screening period 
without prior Sponsor approval. Ot her laboratory tests not direc tly affecting pa tient eligibility 
may be repeated at the Inves tigator‚Äôs discretion during Screen ing. The 24-hour ABPM may be 
repeated if there is a technical problem with the test.  
If a patient is rescreened, they must sign a new informed consent form (ICF) and be assigned a 
new screening ID each time. 
4.4 Early Patient Discontinua tion or Withdrawal  
Patients may withdraw their consen t to participate in the study at  any time for any reason without 
prejudice. The Investigator should make reasonable attempts to retain the pa tient in the trial and 
to document the specific reason why consent is withdrawn.  
x Patient must be discontinued from the st udy if the patient becomes pregnant (see 
Section  8.11). 
Patients should be discontinued from the study if the patient re quires or starts a prohibited 
medication(s), or is not adhe ring to protocol procedures. 
The Investigator can also withdraw patients from the study.  
Reasons may include, but are not limited to: 
x The Investigator decides it is in the patient‚Äôs best interest to disc ontinue study drug and/or 
participation in the study. 
x The patient experiences an AE or any of the special safety events outlined in Table 2 , 
Section  5.4.1 that the Investigator believes requires withdrawal from the study. 
x Patient is lost to follow-up. Before a patie nt is determined to be lost to follow-up, 
reasonable efforts will be made to contact the patient and comple te study termination 
procedures. 
If a patient discontinues early from the study, the pa tient will complete an early termination (ET) 
visit at the time of last dose of study drug or within 2 weeks. They will be instructed to return to 
the site for the Week 22 visit per their origin al dosing schedule, and for the follow-up visit 28 
days after the last dose of study drug. Depending on the timing of the patient‚Äôs discontinuation, 
the visits may happen out of sequenc e, and either visit may serve as  the patient‚Äôs last study visit. 
Patients who discontinue study drug early should be encouraged to complete the end of treatment 
and follow-up assessments and to report any AEs, including SAEs , for 28 days after the last 
administration of study drug. The date when the patient discontinues study drug and the reason 
for discontinuation must be recorded on the electronic case report form (eCRF).  
For patients who withdraw consent to participate in the study, every effort should be made to 
determine whether the withdrawal of consent was re lated to an AE or a specific aspect of the 
study. If a patient wishes to withdraw consent to further participation in the study entirely‚Äî
including Follow-up, this should be clearly document ed (1) in the patient‚Äôs medical record and 
signed by the Investigator and (2) in the eCRF. 
Before a patient is determined  to be lost to follow-up, reas onable efforts (i.e., 3 documented 
attempts) will be made to contact the patient and complete study termination procedures. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 40 of 105 For guidelines about temporary interruption of study drug or study drug modifications, see 
Section  5.4. 
A patient may be withdrawn early from the study if the study is terminated early by the Sponsor 
or regulatory authority.  
4.5 Replacement of Patients 
Patients who withdraw from st udy early will not be replaced. 
4.6 Restrictions During Study 
4.6.1 Dietary Restrictions 
The assigned dose will be administered orally once daily in the morning or at bedtime, with no 
food for 4 hours before and 1 hour after dosing. Any other medication(s) that the patient is 
taking should be taken 30 minutes after the dose of study drug. Each dose should be taken with 240 mL water. 
4.6.2 Contraception 
All female patients of childbearing potential (i ncluding all women <50 years old, women whose 
surgical sterilization was perfo rmed <6 months ago, and wome n who have had a menstrual 
period in the last 2 years) w ill take pregnancy tests at ev ery visit from Screening through 
Follow-up. The Screening pregnanc y test will be a blood test. All subsequent pr egnancy tests 
will be urine tests. 
Female patients of childbearing potential are required to use a highly effective method of 
contraception from 30 days prior to Day 1 to 30 days following the last dose of study-drug 
administration. Male patie nts with female partners are re quired to use to use 2 forms of 
contraception, one of which is a barrier method, from Day 1 (prior to study drug administration) 
until 30 days following the last dose of study drug administration.  
Highly effective forms of contraception include:  
x Abstinence 
x Surgical sterilization  
x Intrauterine device or intrauterine system  
x Oral contraception plus a barrier method  
x Double-barrier method (e.g., male condom or a diaphragm plus a vaginal spermicidal 
cream) 
If a patient is usually not sexua lly active but becomes active, they, with their partner, must 
comply with the contraceptive requirements detailed a bove. In addition, male  patients should not 
donate sperm until 30 days after the last dose of study drug.  
4.6.3 Surgery during the Study 
Patients may not undergo unilateral or bilatera l adrenalectomy or nodulectomy from Screening 
through the follow-up visit. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 41 of 105 5 STUDY TREATMENTS AND MANAGEMENT 
5.1 Study Drug and Placebo 
Study drug is defined as relacor ilant or placebo equivalent. 
Relacorilant and placebo equi valent, including dose and regime n, formulation, packaging, and 
storage, are described in Table 1 .  
Table 1 Study Drug and Placebo: Desc ription, Administration, Packaging, 
and Storage 
 Study Drug and Placebo 
Specifications Rela corilant Placebo 
Description  For each capsule, relaco rilant is prepared 
as a  
 
  The placebo for relacorilant capsule is designed 
to match the study drug in appearance. Each placebo capsule contains a formulation of 
 
 
Supplied Capsules, 28-count in child-resistant, blister-packaged ca rds and labeled per 
country requirement. Capsules, 28-count in child-resistant, blister-packaged cards and labeled per country requirement. 
Appearance Yellow, oblong,  capsules Yellow, oblong  capsules 
Unit dose strength 100 mg relacorilant/capsule Placebo equivalent 
Dose levels 100, 200, 300, or 400 mg Placebo equivalent 
Administration  Orally, with 240 mL of water under fasted conditions Orally, with 240 mL of water under fasted conditions 
Regimen 4 capsules, once daily a 4 capsules, once daily a 
Restrictions  Refer to  Section  4.6.1  Refer to Section  4.6.1  
Dispensing study drug Dispense to patients at the visits specified in Appendix A   Dispense to patients at the visits specified in Appendix A   
Storage Store as follows:  
x In a secure location 
x At  Excursions 
permitted,   
x Out of reach and sight of children Store as follows:  
x In a secure location 
x At  Excursions 
permitted,   
x Out of reach and sight of children 
Note: Procedures for inventory, reconciliation, and destruction or return of study drug are provided in Section  11.6. 
a. No matter which arm patients are randomized, every patient  will take 4 capsules at each dose every day. The study 
drug is provided in a blister pack containing 28 capsules divided into 7 rows (Days 1 to 7). For patients 
randomized to relacorilant, each row will contain either a mix of relacorilant capsules and placebo capsules to 
ensure the patient gets the correct dose (i.e., for 300 mg of relacorilant, each row contains 3 relacorilant capsules 
and 1 placebo capsule), or the row will contain 4 relacorilant capsules (i.e., for 400 mg of relacorilant). For patients randomized to placebo, all 28 capsules in the blister pack contain placebo capsules. Patients must take all 4 capsules to ensure they get the full dose. 

Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 42 of 105 5.2 Non-Investigational Medicinal Agent 
Not applicable.  
5.3 Dose-Escalation Process 
During dose escalation, all patients will be escalated in a step wise manner from 100 mg to 
400 mg once daily, based on tolerability a nd improvement in hype rglycemia and/or 
hypertension. The starting dose at Baseline will be 100 mg relacorilant or matching placebo 
once daily for 2 weeks, after which the dose w ill be increased to 200 mg. Then the dose will 
increase in 100 mg increments every 4 weeks. Do se titrations after Week  18 are not permitted. 
Dose escalation will be performed based on tolerability assessed by the unblinded Medical 
Monitor considering the following factors (only in patients whose current dose is well tolerated). 
In patients with DM/IGT only, the 2-hour glucose based on oGTT: 
x is ¬ï140 mg/dL or 
x is <140 mg/dL and KDVQRWGHFUHDVHGE\¬ïPJG/IURP%DVHOLQH  
In patients with systolic hypertension only, th e average 24-hour systolic BP (based on 
ABPM): x is ¬ï130 mm Hg or 
x is <130 mm Hg and KDV QRWGHFUHDVHGE\¬ïPP  Hg from Baseline 
In patients with both DM/IGT and systolic hypertension: x The 2-hour glucose of the oGTT: 
x is ¬ï140 mg/dL or 
x is <140 mg/dL and KDVQRWGHFUHDVHGE\¬ïPJG/IURP%DVHOLQH  
OR 
The average 24-hour systolic BP (based on ABPM): 
x is ¬ï130 mm Hg or 
x 
is <130 mm Hg and has not decreased by ¬ï5 mm Hg from Baseline 
Dose escalation may be held if the patient cannot safely tolerate escalation to the next dose.  
If access of patients to the study site is restricted due to the COVID-19 pandemic, dose 
escalation up to 200 mg may occur remotely if necessary. Subsequent dose escalations, however, 
are permitted only after completion of safety assessments. 
Dose escalations start the day after the visit at  which they are approved by the Investigator.  
Results of 2-hour oGTT, ABPM, a nd safety laboratory results w ill be reviewed by an unblinded 
Medical Monitor to monitor patient safety a nd allow dose escalation. The unblinded Medical 
Monitor will be unblinded to results of study as sessments but is blinded to the treatment 
assignment. The Sponsor or designee, the Inves tigator, the blinded Medical Monitor, study-site 
personnel, and the patient will be blinded to treatment assignment (see  Section  5.8).  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 43 of 105 5.4 Dose Modifications 
Every effort should be made to administe r study drug on the planned dose and schedule. 
However, if in the opinion of the Investigator  a relacorilant dose is not tolerated, a dose 
interruption or dose reduction is permitted. Re-escalation after a dose reduction is permitted, 
with the approval of the Medical Monitor. 
Dose reductions to manage excessi ve GR antagonism are detailed in Section  5.4.2. 
Dose interruption or dose reduction to a previous dose may occur at any time.  
During study-drug interruptions, patients will continue on the same  visit schedule.  
5.4.1 Dose Interruption and/or Discontinuation: Special Safety Events 
Based on the mechanism of action of relacorilant, there is a theoretical risk of excessive GR 
antagonism, which could manifest with findings such as weakness, tiredness, dizziness, weight loss, nausea, vomiting, or muscle aches. Because relacorilant does not affect the MR, it is 
unlikely that hypotension would occur in the absence of antihypertensive medication. 
The actions outlined in Table 2  should be taken if a patient: 
x Exhibits signs and symptoms of excessive GR antagonism 
x Experiences significant trauma, surgery, or medical illness occurring at any time during 
the study (through 2 weeks after last dose) 
At study enrollment, all patients w ill be given a card to carry with them that identifies their 
potential risk for excessive GR antagonism. The card will contain the following information: 
x Mention use of relacorilant (‚Äúgl ucocorticoid receptor antagonist‚Äù) 
x Potential need for glucocorticoid use in setting of shock, surgery, serious illness, or injury 
x Recommended dose of replacement steroids (4 ‡ØÖ10 mg dexamethasone intramuscularly or 
intravenously for 2‚Äì3 days as needed) 
x Investigator contact information.  
 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 44 of 105 Table 2 Criteria for Dose Modification or  Discontinuation Due to Special Safety 
Events 
 Criteria for Interrupting and Restarting or Modifying 
Study Drug and Patient Management Criteria for Stopping Study 
Treatment 
Excessive GR 
antagonism Criteria : Signs and symptoms of excessive GR antagonism 
Management:  
Immediately interrupt relacorilant treatment for at least 3 days 
and start standard supportive care, including fluid 
resuscitation, as indicated. 
If appropriate, administer supplemental glucocorticoids given 
in high doses to overcome the GR antagonism produced by relacorilant. Initially, consider parenteral dexamethasone  (4‡ØÖ10 mg), followed by additional parenteral or oral doses 
once or twice daily for 1 ‡ØÖ3 days and tapered thereafter, 
depending on clinical response. In some cases, higher doses of dexamethasone for longer periods of time may be required. 
If the patient has been rece iving treatment with a MR 
antagonist, consider discontinuing it or adjusting the dose, 
particularly in the presence of hypotension.  
Restart relacorilant treatment only if the potential benefits 
outweigh the risks and after a discussion with the Medical Monitor.  
Restart relacorilant at the highest dose previously tolerated by 
the patient.  
After 2 weeks, resume the current dose or increase by 100 mg 
with the approval of the Medical Monitor.  A combination of at least 2 of 
the following Grade 3 or higher events can lead to stopping/reducing dose: fatigue, anorexia, nausea/ 
vomiting 
a (associated with 
decreased oral intake), or 
abdominal pain, seen either at the 200-mg dose level or at other dose levels for which the Investigator deems dose reduction is not an option. 
Significant trauma, surgery, or medical illness at any time during the study (through 2 weeks after last dose) Management: 
As medically indicated, interrupt relacorilant treatment and 
provide supplemental glucocorticoids to offset the glucocorticoid receptor antagonism even in patients not experiencing signs and symptoms of excessive antagonism.  
After resolution of the physiological stress associated with the 
event and if still within the Treatment Period, resume relacorilant at the last dose level the patient was receiving 
before interruption.  
GR, glucocorticoid receptor; MR , mineralocorticoid receptor. 
a. For the purpose of this assessment, nausea and vomiting are considered 1 criterion. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 45 of 105 5.4.2 Pharmacokinetic Criteria for Dose  Adjustment or Discontinuation 
Not applicable. 
5.5 Concomitant Medications 
Concomitant medications are defi ned as any prescription or over-the-counter medication, herbal 
preparations, and vitamin and/or mineral supplements that the patie nt began or continued in the 
period starting with the first dose of study drug on Day 1 and ending at the follow-up visit. 
Medications that the patient star ted and ended before the first dos e of study drug will be noted as 
prior medications.  
At Screening, a list of current medications w ill be obtained, including st art date, dosage, and 
route of administration, along with  any medications taken in the 3 months before Screening to 
treat Cushing syndrome, diab etes, and/or hypertension. 
Antidiabetic, antihypertensive, antid epressant and/or lipid-loweri ng medications that are highly 
dependent on CYP3A for clearance and cannot unde rgo dose modifications on coadministration 
with strong CYP3A inhibitors are prohibited. Strong CYP3A4 inducers are also prohibited. 
For example, the FDA provides a current list of Substrates and Inducers of CYP3A at the 
following website.  
https://www.fda.gov/drugs/developmentapprovalpro cess/developmentresou rces/druginteracti
onslabeling/ucm093664.htm#table4-1 
The list may not be inclusive of all currently available substrates and inducers of CYP3A worldwide. The Investigator should contact the Medical Monitor with any questions.  
Patients on such medications at Screening will need to have their dose adjusted or be switched to 
an alternative medication. For pa tients switched to an alternative antidiabeti c or antihypertensive 
medication, there must have been no increase in medication dosage for at least 4 weeks prior to 
first dose of study medication (see Table 3 ). 
Information about concomitant me dications will be collected from  all patients at each visit from 
Screening through the Follow-up Visit. If access of patients to the study site is restricted due to 
the COVID-19 pandemic, a review of concomitant medications may involve  alternative methods 
(e.g., phone contact or virtual study visits). Any ch anges in medications si nce the last visit will 
be captured and recorded.  
Efficacy assessments include the total daily dose of insulin for patients with DM/IGT and 
antihypertensive medications for pa tients with uncontrolled hypertension. 
Permitted concomitant medications are listed in Table 3 . 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 46 of 105 Table 3 Permitted Concomitant Medications 
Medication Use and/or Restriction 
Mineralocorticoid receptor 
antagonists and other potassium-sparing diuretics Do not initiate or increase dose without prior consultation with the Medical Monitor. 
Potassium supplements To treat hypokalemia 
Insulin and oral antidiabetic medication Do not take before the oGTT on the day of the procedure; can be taken with food after oGTT is completed 
Dose can be decreased during study-drug dosing to prevent 
hypoglycemia; upward titration should be avoided and may occur only 
after consultation with the Medical Monitor. 
Long-acting insulin Can take the night before the oGTT. 
Antihypertensive medication Dose can be decreased during the study-drug dosing to prevent 
hypotension or orthostatic symptoms.  
Do not increase dose or add new antihypertensive medications without 
prior consultation with the Medical Monitor. 
Lipid-lowering drug No increases in current dose allowed from 4 weeks before Baseline 
through the follow-up visit.  
oGTT, oral glucose tolerance test.  
5.5.1 Rules for Use of Antidiabetic and Antihypertensive Concom itant Medications 
x Patients should not take antid iabetic medications before the oGTT on the day of the 
procedure; antidiabetic medica tions may be taken with food after the oGTT is completed. 
Long-acting insulin may be taken the prior evening. 
x If any modification of existing diabetes medications or initiation of new diabetes 
medication is being considered during dosing, a 2-hour oGTT glucose should be obtained 
prior to modification of medications. 
x Unblinding of fasting or postprandial gluc ose from the 2-hour oGTT or unblinding of 
ABPM results will not result in the unblinding of study treatment. 
x If any modification of existing antihypert ensive medication or  initiation of new 
antihypertensive medication is being cons idered during dosing, an ABPM should be 
performed prior to modification of medications. 
5.5.1.1 Decrease or Discontinuation of Concomitant Medications 
In patients with DM/IGT at Baseline 
Reduction or discontinuati on of insulin and insulin secretagogue s should be considered only if:  
x Fasting or postprandial blood glucose <70 mg/dL on at least 2 home measurements, or 1 serum glucose measurement associ ated with symptoms of hypoglycemia 
 For basal and prandial insulin, consider decreasing dosage by 20%. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 47 of 105  For insulin secretagogues, consider decreasing dosage by 50%; discontinue 
if recurrent. 
 Reductions of insulin and/or  insulin secretagogues can be adjusted depending on the 
degree of hypoglycemia and the cu rrent total dose of insulin. 
x In patients with hypoglycemia unawareness, changes in insu lin and insulin secretagogues 
should be considered if fasting or postprandial glucose is <70 mg/dL on at least 2 home 
measurements or 1 serum glucose measurement.  
Every effort should be made to obtain an oGTT prior to a reduction in anti-diabetic medication 
(if patient‚Äôs condition allows it).  
The unblinded Medical Monitor will notify the site of the pre-challenge fasting or 2-hour glucose 
from the oGTT decreases below 70 mg/dL.  
Unblinding of pre-challenge fasting or the 2-hour glucose of the oGTT will not result in the 
unblinding of study treatment. 
In patients with uncontrolled sy stolic hypertension at Baseline 
Reduction or discontinua tion of antihypertensive medications should be considered only if: 
x Blood pressure decreases below 100 mm Hg sy stolic or 60 mm Hg diastolic by office 
measurement on at least two measurements obtained 15 min apart with symptoms of 
orthostatic hypotension.  
x Symptoms of hypotension (includi ng orthostatic hypotension) occur. 
Every attempt should be made to obtain an ABPM prior to any decrease of BP medication (if 
patient‚Äôs condition allows it). The unblinded Medical Monitor will notify the si te if BP decreases below 100 mm Hg average 
SBP or 60 mm Hg mean diastolic by ABPM. 
Unblinding of ABPM results will not re sult in the unblinding of study treatment. 
5.5.1.2 Increase or Initiation of Concomitant Medication 
In patients with DM/IGT at Baseline 
Increases in, or initiation of, antidiabetic medications used as rescue medication are allowed if 
patients meet one of the following criteria:  
Local laboratory based on standard of care a ssessments (serum glucose and/or HbA1c):  
x Morning fasting glucose >300 mg/dL on ¬ï2 consecutive days  
x HbA1c >12% 
Central laboratory study re lated assessments (serum glucose, HbA1c and/or 2-hour oGTT):  
Results will be reviewed by an unb linded Medical Monitor to monitor patient safety. If a patient 
meets at least 1 of the following criteria, the results will be communicated to the study site, and 
rescue medication may be initiated or increased.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 48 of 105 x Morning OR pre-challenge fasting gluc ose from the 2-hour oGTT >300 mg/dL 
x HbA1c >12% 
x Pre-challenge fasting glucose increases  by 50 mg/dL AND the 2-hour oGTT glucose 
increases by 100 mg/dL from Baseline 
If antidiabetic medication dose is increased or medication is initiated dur ing the study, oGTT and 
HbA1c tests will be performed per the protocol schedule. 
In patients with uncontrolled syst olic hypertension at Baseline: 
Increases in, or initiation of, anti hypertensive medications used as  rescue medication are allowed 
if patients meet one of the following criteria (based on standard-of-care measurements):  
x Mean office SBP >170 mm Hg or DBP >110 mm Hg on ¬ïPHDVXUHPHQWV REWDLQHG
15 minutes apart  
x Average SBP >170 mm Hg or DBP >110 mm Hg  based on standard of care ABPM  
Study ABPM results will be reviewed by an unblinded Medical Monitor to monitor patient 
safety. If a patient meets the following criteri on, the results will be communicated to the study 
site, and rescue medication may be initiated or increased:  
x Average SBP >170 mm Hg or DBP >110 mm Hg 
Unblinding of ABPM results will not resu lt in the unblinding of study treatment.  
If antihypertensive medication dose is increased or medication is initiated during the study, 
ABPM tests will be performed per regular schedule.  
5.6 Prohibited Medications 
Relacorilant is a strong inhibitor of CYP3A. Medications that are highly dependent on CYP3A 
for clearance for which elevated plasma concentr ations are associated with SAEs and for which 
dose modification is not an option with strong CYP3A ‚Äòinhibitors‚Äô should be avoided (consult the prescribing information of the respective concomitant medications for further details). 
Additionally, the following medications used in the treatment of Cushing syndrome are 
prohibited during treatment w ith study drug in this study: 
x Adrenostatic medications: me tyrapone, osilodrostat, ke toconazole, fluconazole, 
aminoglutethimide, mitotane, or etomidate. 
x Mifepristone. 
x Strong CYP3A4 inducers.  
x Antidiabetic, antihypertensive, an tidepressant, and/or lipid-low ering medications that are 
highly dependent on CYP3A for clearance and cannot undergo dose modifications upon 
coadministration with strong CYP3A inhibitors.  
x Systemic glucocor ticoids (with the exception of tempor ary use for treatment of excessive 
GR antagonism), potent (gr oup III) topical corticosteroids in extended body surface 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 49 of 105 areas, and intra-articular corticosteroids unless other treatment options 
fail/contraindicated. 
x Other investigational agents. 
5.7 Method of Treatment Assignment and Randomization 
Eligible patients will be  randomized 1:1 to relacorilant or  placebo and stratified by one factor 
(disease at Baseline) with 3 levels:  
x DM/IGT only at Baseline  
x Systolic hypertension only at Baseline  
x DM/IGT and systolic hypertension at Baseline 
Randomization will be centrally assigned using . The log-in 
information and directions for the  will be provided to each site. 
Study drug will be dispensed at the study visits summarized in Appendix A . Returned study drug 
should not be re-dispensed to the patients. Statisticians involved in  generation of randomization codes, or who have access to the 
randomization code will not  be involved in the analyses of the study. 
5.8 Blinding/Unblinding 
The Sponsor or designee, the Investigator, the blinded Medical Monitor,  study-site personnel, 
and the patient will be blinde d to treatment assignment. Se lected study-assessment and 
laboratory results (as described in Section  6) that could potentially reveal the treatment 
assignment in some patients will remain blinded until after database lock.  To maintain the overall quality and blinding of the clinical trial, unblinding of treatment 
assignment should occur only in exceptional circ umstances. If unblinding treatment assignment 
is deemed necessary, the Investigator should complete the unblinding process through the , 
or, if the  is unavailable, contact the emergency unblinding toll-free number, which can be 
found in the study manual. The Investigator should notify the Sponsor of any unblinding 
occurrences. 
 
 
 
 
 
 
 
 
 

Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 50 of 105  
 
Investigators wishing to discuss potential unb linding should contact the Me
dical Monitor for 
further discussion.  
If unblinding of either central laboratory or ABPM data is required, the site should refer to the 
respective manual for the unblinding process.  
Note: Even if laboratory values or ABPM values are unblinded, the treatment assignment will 
remain blinded.  
The Investigator is encouraged to maintain the blind as far as possible. The patient‚Äôs treatment 
assignment must not be disclosed to the patient and/or other study staff. There should not be any 
written or verbal statements of the patients‚Äô treatment assignment in any patient documents.  
If any accidental unblinding occurs for treatme nt assignment or bli nded laboratory/ABPM 
values, the Investigator should promptly docum ent the occurrence and notify the Sponsor.  
5.9 Dosing Diary 
A dosing diary will be dispensed at the time points specified in Appendix A  for patients to record 
each self-administered dose of  study drug and any concomitant  medications. Entries should 
include the number of capsules as well as the date and time of study dr ug administration. Time 
and dose administered should be doc umented in the clinic charts. 
Patients will be instructed to return all unused study drug and the dosing diary at the patient 
visits. 
5.10 Product Accountability a nd Treatment Adherence  
The Investigator is responsible for the acc ountability of all used and unused study drug. All 
investigational materials should be  kept in a secure area inacce ssible to unauthorized individuals. 
Drug accountability records must be maintained at the site and be available for monitoring by the 
Sponsor or its representatives. At a minimum, reco rds will be maintained to document receipt of 
supplies, dispensing of supplies to specific patie nts, and return of unused product by patients.  
After study drug accountability monitoring has oc curred, opened and unopened cartons of study 
drug must be returned to the Sponsor or its desi gnee at the end of the study or destroyed onsite 
upon approval from Sponsor, in accord ance with local requirements. 
Under no circumstances will the Investigator a llow the study drug to be used other than as 
directed by the protocol. 
Adherence to the study drug regimen will be determined by review of the dosing diary and 
counting the number of capsules taken and returned at each study visit. 
5.11 Continued Access to Study Treatment 
All patients completing the study will be eligible to enter an ex tension study provided that they 
have at least 80% adherence with scheduled dosing (by capsule counts). 

Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 51 of 105 5.12 External Data Review Committee 
5.12.1 Independent Data-Monitoring Committee to Monitor Patient Safety 
An Independent Data Monitoring Committee (IDM C) will be establishe d to conduct periodic 
reviews of data to ensure the safety of patients. The IDMC will be composed of at least 3 voting 
members: two physicians and one statistician. The IDMC will meet at l east quarterly. Further 
details describing the IDMC composition, conten ts of data reports,  responsibilities, and 
decision rules will be described in the IDMC Charter and actions taken will be documented in meeting minutes. 
5.13 Monitoring of and Treatment for Electrolyte Abnormalities and Edema 
Monitoring for electrolyte abnormalities occurs at  every visit and any clinically significant 
abnormality should be treated per standard of care. 
Monitoring for edema occurs at every visit duri ng a physical examination and should be treated 
per standard of care.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 52 of 105 6 DESCRIPTION OF STUDY ASSESSMENTS AND PROCEDURES 
Study procedures and their timing are summarized in Appendix A . Protocol waivers or 
exemptions are not allowed.  
The Investigator and Sponsor  will conduct the study in accordance with ICH Good Clinical 
Practice (GCP) and local regula tions. Adherence to the study-de sign requirements is essential 
and required for study conduct, and the Investigator must ensure that trial procedures are 
performed as described in the protocol. During the study, procedures and observations will be 
monitored to confirm that st udy requirements are being followed as outlined in the SoA. 
In the event that a patient is unable to come to the clinic to participate in study-related visits or procedures due to the COVID- 19 pandemic, Sponsor-approved alternative options may be 
provided to the Investigator site s based on the needs and safety of  patients. This may include the 
provision of study drug dispensation a nd delivery outside of the clinic. 
6.1 Informed Consent and Screening 
Written informed consent must be obtained be fore initiating any study- mandated procedures. 
If allowed by local regulatory authority, remote consenting will be permitted if access of 
patients to the study site is restricted due to the COVID-19 pandemic. IRB/EC guidelines 
should be followed. 
All screening evaluations must be completed and reviewed to confirm that potential patients 
meet all eligibility criteria.  
6.1.1 Dexamethasone Suppression Test 
The dexamethasone suppression test (DST) will be performed at Screening. Dexamethasone will 
be administered either as a 1-mg (or higher) dose overnight or a 2-mg dose over 48 hours; a 
blood sample will be drawn and will be tested at a central la boratory. In special circumstances 
pre-approved by the Sponsor, a blood sample may be  tested at a local la boratory. Dexamethasone 
levels should be measured concurrently. 
Estrogen preparations that affect significantly th e cortisol binding globulin levels, including birth 
control and hormone replacement treatments, should be  held for a duration of at least 5 half-lives 
of the estrogen analogue prior to DST.  
6.1.2 Adrenal-Imaging History 
Confirmation of a benign adrena l lesion can be made from the most recent imaging obtained as 
part of standard of care (within three years prior to Screening).  
If the imaging report or the actual imaging study is not available, an adrenal imaging study 
should be performed to confirm study e ligibility before dosing with study drug. 
6.1.3 History Cushing-Syndrome ‡ØÖMedication Washout 
Medications used in the treatment  of hypercortisolism are prohibited and require washout of at 
least 12 weeks before Screening. Patients requi ring washout of a medication for Cushing 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 53 of 105 syndrome must complete the Screening/Base line oGTT, HbA1c, and 24-hour ABPM after 
washout and within 2 weeks before Day 1 dosing. 
6.1.4 Demographics and Baseline Disease Characteristics 
Patient demographic data, including age at time of informed consent, sex, and race/ethnicity, and 
baseline disease characteristics, such as years since diagnosis of hypercortisolism (e.g., primary 
pigmented nodular adrenocortical disease, primary macronodular adrenal hyperplasia, adrenal 
adenoma), will be documented.  
6.1.5 Medical and Medication History 
Relevant patient medical  history, including the diagnosis, etiology, and treatment history of 
hypercortisolism (including dexa methasone suppression test fa ilure where appropriate), 
diagnosis of DM/IGT and/or hypertension, as well as other illnesses and al lergies, date(s) of 
onset, and whether conditions are currently ongoing will be recorded at Screening and Baseline 
(Appendix A ). Adrenal surgical history will include date and type.  
A menstrual history will be obtained for all female patients at Screening. 
At Screening, a list of current medications w ill be obtained, including st art date, dosage, and 
route of administration, along with  any medications to treat hyperc ortisolism, diabetes, and/or 
hypertension taken in the 3 months prior to Day 1. 
6.2 Safety Assessments 
Safety will be dete rmined from evaluation of AEs, physical examinations, clinical laboratory 
tests, vital signs, and ECGs.  
6.2.1 Physical Examination  
A comprehensive physical examination will be pe rformed. If clinically significant abnormalities 
are observed during Screening, they should be repo rted in the patient‚Äôs medical history; if 
observed any time after the first dose of study drug  (Day 1), they will be considered treatment-
emergent AEs.  
Investigators will assess the general physical ap pearance of patients during the examination. 
6.2.2 Vital Signs 
Vital signs, including BP, heart rate, respiratory rate, and body temperature, will be obtained at 
the time points specified in Appendix A . Blood pressure will be measured in both arms at 
Screening and the arm with the higher reading will be recorded and used for all subsequent 
measurements. Blood pressure and heart rate will be  taken after the patient has rested in a sitting 
position for approximately 15 minutes and ¬ï30 minutes after smoking or caffeine intake. 
Automated BP machines can be used to standardize measurements. 
Unscheduled assessments of  vital signs can be pe rformed as necessary.  
To determine whether an increase in or initiati on of antihypertensive medication is needed for 
patients with hypertension, office blood pressure m easurements may be coll ected. At least three 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 54 of 105 blood pressure measurements sepa rated by an interval of 15 minut es in the designated arm are 
required. If 2 sequential readings differ by >5 mm Hg (systolic or diastolic), repeat the 
measurement until consecutive readings are within 5 mm Hg of each other.  
In addition to the safety vital signs collected, a 24-hour ABPM will also  be done by all patients 
at Screening and by patients with hypertension ( Section  6.4.2) during treatment at the time points 
specified in Appendix A . 
6.2.3 Height, Weight, and Waist Circumference 
Body weight and waist circumfe rence will be measured for a ll patients at the time points 
specified in Appendix A . Weight will be measured without overcoat and shoe s and with only 
light clothing. Clinical sites will be provided with tape measures to ensure consistency of waist 
circumference measurements. Wa ist-circumference measurements  should be obtained to the 
nearest 0.5 cm (1/4 inch) following removal of cl othing from the waistline. Detailed instructions 
for measurement of waist circumferenc e will be provided in the study manual. 
Body weight, measured without overcoat and shoes and with  only light clothing, will be 
measured at every visit.  
Height will be measured only at Screening ( Appendix A ).  
6.2.4 Electrocardiogram 
Twelve-lead ECG tracings will be obtained from a ll patients in duplicate at the visits noted in 
Appendix A . Patients should lie down for ¬ï10 minutes before each ECG evaluation.  
On days when study drug is administered, th e ECG should be perform ed 2 hours (¬±30 minutes) 
after study-drug dosing. A Sponsor-approved alternative option for EC Gs (i.e., use of alternative 
locations for assessment) is permitted in the event of site closures due to the COVID-19 
pandemic. 
The Investigator or designee will indicate in the source documents whether the ECG was normal, 
abnormal but not clinically significant, or a bnormal and clinically si gnificant. Any new or 
worsened abnormality noted as clinically significant will be reported as an AE. 
In patients with an abnormal QTc interval at  Screening, in which no concomitant drugs known 
to prolong QTc and no electrolyte abnormalities ar e present, duplicate ECG recordings should be 
obtained. The final decision to exclude a patient should be based on the average QTcF interval 
across the recordings. If an electrolyte abnormality is present, it should be corrected before the 
ECG is repeated. If the patient is taking a concomitant medication known to cause QT prolongation, an alternative medi cation may be considered, and the ECG repeated after an 
appropriate washout period.  
Electrocardiogram data will be submitted to a central reviewer; instruction will be provided in 
the study manual. 
6.2.5 Adverse Events 
Details on definitions and re porting of AEs are provided in  Section 8. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 55 of 105 All AEs will be recorded from the time of signing of the ICF until 28 days after the last dose of 
study drug. Patients should be monitored for AEs c onsistent with the current Investigator‚Äôs 
Brochure for relacorilant.  
6.2.6 Concomitant Medications 
Review usage and dosage of antidiabetic  and antihypertensive medications. See  Section 5.4 and 
Section  5.5 for rules for use of antidiabetic and an tihypertensive concomitant medications and 
the procedures to accompany any changes. 6.2.7 Clinical Laboratory Assessments 
6.2.7.1 Laboratory Parameters 
Fasting blood samples will be collected for the anal ysis of safety at the time points specified in 
Appendix A . Laboratory samples will be analyzed at 1 or more central laboratories; instructions 
will be provided in the laboratory manual.  
During Screening, the Investigator will review laboratory reports evaluate the results, and 
sign/date the report.  
During dosing, all laboratory asse ssments will remain blinded. The unblinded Medical Monitor 
will review laboratory values and notify the Inve stigator and study-site staff of any significant 
out-of-range laboratory values. Critical lab values will be reported directly  by the central lab to 
the Investigator. The unblinded Medical Monitor will follow up with the site to discuss critical 
laboratory values. To maintain th e blind, investigators should not repeat laboratory tests locally 
unless medically necessary. 
 
Any clinically significant laboratory value will be reported as an AE by the Investigator. Patients with a clinically significant out-of-range laboratory value will be followed until the laboratory 
value returns to normal or becomes medically stable. The Investigator will treat the patient, as medically required, at appropriate intervals until this occurs. 
Laboratory tests to be performed are listed in Table 4  and should be performed according to the 
schedule provided in Appendix A.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 56 of 105 Table 4 Clinical Laboratory Variables Evaluated During the Study 
Hematology 
Red blood cell count  Hemoglobin  Hematocrit  Mean corpuscular hemoglobin Mean corpuscular hemoglobin volume Mean corpuscular volume  Platelet count Mean platelet volume Red-blood-cell distribution and width 
White-blood-cell count  
Neutrophils (percent and absolute) Lymphocytes (percent and absolute) Monocytes (percent and absolute) Eosinophils (percent and absolute) Basophils (percent and absolute) Serum Chemistry Sodium  Potassium  
Calcium  Chloride  Phosphorus  Magnesium  Creatinine Creatine kinase Bilirubin (total and direct) Albumin  Alkaline phosphatase Lactate dehydrogenase Aspartate aminotransferase  Alanine aminotransferase Fasting glucose  Fasting insulin Blood urea nitrogen Uric acid  Bicarbonate  Total protein  Glucocorticoid-Receptor 
Activity 
Potential biomarkers of GR 
activity 
Pregnancy 
Serum/urine pregnancy test 
Thyroid Function Thyroid-stimulating hormone  
Total T3 Reflex Free T4 Reflex 
Glucose Control 2-hour oGTT 
b  
HbA1c 
Biochemical Markers for Bone 
Remodeling 
Serum osteocalcin  Pharmacokinetic Relacorilant 
Coagulation panel a 
Factor VIII von Willebrand factor Protein S Protein C Thrombin antithrombin (TAT) Partial thromboplastin time 
(PTT) Pharmacodynamic 
DST with dexamethasone levels Urinary free cortisol (UFC) Salivary cortisol Hypothalamic-pituitary-adrenal 
(HPA)-axis parameters: 
Plasma ACTH 
Serum DHEA-S 
Fasting serum cortisol  Lipid-Metabolism Panel a 
Total cholesterol Low-density lipoprotein-cholesterol 
High-density lipoprotein-cholesterol 
Very low-density lipoprotein 
cholesterol 
Triglycerides 
ACTH, adrenocorticotropic hormone; DHEA-S, dehydroe piandrosterone sulfate; DST, dexamethasone 
suppression test; GR, glucocorticoid receptor; HbA1c, hemoglobin A 1c; oGTT, oral glucose tolerance test; 
T3, triiodothyronine; T4, thyroxine.  
a. Lipid-metabolism panel and coagulation pane ls should be performed either before or ¬ïKours after DST. 
b. 2-Hour oGTT includes glucose, insulin, and glucagon (at selected visits). 
6.2.7.2 Sample Collection, Preparation, and Shipping 
Instructions for collection, preparation, and shi pping of all laboratory sa mples will be provided 
in the study laboratory manual.  
Shipping instructions for samples collected for PK analysis and GR activity biomarkers will also 
be provided. Long-term retention of biological samples is described in Section  11.5.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 57 of 105 6.2.7.3 Blood-Volume Summary 
Blood samples will be used for analysis of safe ty laboratory, efficacy, PK, PD, biomarker, and 
pharmacogenetic parameters. The to tal volume of blood to be collect ed from each patient will be 
no more than 505 mL for his/her entire study participation. 
6.3 Pregnancy Test 
All female patients of childbearing potential (i ncluding all women <50 years old, women whose 
surgical sterilization was perfo rmed <6 months ago, and wome n who have had a menstrual 
period in the last 2 years) w ill undergo pregnancy tests at ev ery visit from Screening through 
Follow-up. The Screening pregnancy test will be a blood test; all s ubsequent pregna ncy tests will 
be urine tests, as specified in Appendix A . 
6.4 Efficacy Assessments 
The key efficacy assessments in this study ar e effects on glucose tolerance in the impaired 
glucose tolerance/diabetes subgroup and the ef fects on BP in the hypertensive subgroup. All 
other effects assessments are considered exploratory. Table 5  lists all efficacy assessments. 
Details are provided below.  
Table 5 List of Efficacy Assessments 
AUC glucose  Reduction in concomitant medications for DM or 
hypertension 
Glycated hemoglobin (HbA1c) concentration Systolic blood pressure (based on ABPM) 
Fasting glucose Diastolic blood pressure (Based on ABPM) 
Fasting insulin Hormonal and menstrual cycle 
2-hour oGTT 
 glucose, insulin, and glucagon (glucagon at select 
timepoints) Serum osteocalcin 
Plasma ACTH Bone density 
Serum DHEA-S Trabecular bone score 
Fasting serum cortisol Body composition 
Late-night salivary cortisol Factor VIII 
Early-morning salivary cortisol von Willebrand factor 
Beck Depression Inventory Protein S 
Cushing QoL questionnaire Protein C 
Sit-to-stand test Thrombin antithrombin (TAT) 
Trail-making test Partial thromboplastin time (PTT) 
 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 58 of 105 6.4.1 Glucose Tolerance 
A 2-hour oGTT will be used to assess the effect  of study drug on glucose tolerance, insulin 
resistance indices, a nd hyperglucagonemia (AUC insulin, Matsuda Index, HOMA IR, and at 
selected visits AUC glucagon ) following an 8-hour fast at the time points specified in Table 11 .  
In general, patients should not ta ke antidiabetic oral medication or insulin the morning of their 
visit, however, long-acting insulin  can be taken the night before . Oral antidiabetes medications 
and insulin preparations can be taken with food after completion of the oGTT. 
During the 2-hour oGTT, blood samples for plas ma glucose, insulin, and glucagon will be 
collected before the glucose drink and 0.5, 1.0, 1.5, and 2.0 hours after the glucose drink (see 
Table 6 ).  
In patients with an increase to their DM medications before or during Screening, oGTT should 
EHSHUIRUPHG¬ïZHHNVDIWHUWKHL QFUHDVHLQWKHGLDEHWHVPHGLFD WLRQ and within 2 weeks prior to 
the Baseline Visit R*77GXULQJ6FUHHQLQJVKRXOG EH SHUIRUPHGHLWKHUEHIRUHRU¬ï  Kours after, 
the DST test. 
Table 6 Time Window for Collectio n of 2-hour oGTT Blood Samples  
Nominal Time Reporting Standards 
0.5, 1.0, 1.5, and 2.0 hours post glucose drink ¬±10 minutes 
6.4.2 Ambulatory Blood Pressure Monitoring (ABPM) 
The 24-hour ABPM will be assesse d for patients with an increase to their anti-hypertension 
medications either before or during Screening, ABPM VKRXOGEHSHUIRUPHG ¬ïZHHNVDIWHUWKH
increase and within 2 weeks prior to the Base line Visit. ABPM during Screening should be 
SHUIRUPHG HLWKHUEHIRUH RU¬ïK ours after, the DST test. At least 2 attempts should be made to 
obtain an accurate ABPM in all patients enrolled in the study. 
Average 24-hour systolic and diastolic ambulator y BP will be obtained by the patient at home 
using an ambulatory BP monitor provided and in itiated at the study site (or under the condition 
of a Sponsor-approved alternative option in the even t a patient is unable to come to the study site 
due to the COVID-19 pandemic) at the time points specified in Appendix A . The patient should 
use the monitor during a time when a full 24-hour  recording can be completed. The patient 
should perform the ABPM under consistent conditions throughout the study. In cases where the 
ABPM fails QC and needs to be repeated, initiation of the ABPM at home will be allowed. The 
monitor should be worn on the non-dominant arm.  Please see the vendor manual for additional 
details. 
The patient will bring the monitor to each study vi sit or will send it to th e study site in advance 
of the next study visit. ABPM should be initiated at the end of the visit after collection of blood 
samples at each study visit with the exception of  the Week 22 Visit where the ABPM should be 
performed within 7 days prior to the visit. If  more than 2 consecutive hours, or 5 hours over the 
entire period are missing, then the data are consid ered missing, and test should be repeated. The 
results of 24-hour ABPM will remain blinded.  
Standard-of-care ABPM may be performed as ne eded in the opinion of the Investigator.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 59 of 105 6.4.3 Glycated Hemoglobin (HbA1c) 
Blood samples will be collected to measure HbA1c,  a glycoprotein whose concentration reflects 
the amount of glucose bound to hemoglobin. In pa tients who have an increase to their DM 
PHGLFDWLRQVEHIRUHRUGXULQJ6FUHHQLQJ+E$FVKRXOGEHSHUIRU PHG¬ï weeks after the 
increase in diabetes medication and within 2 weeks prior to the Baseline Visit.  
6.4.4 Hypothalamic-Pituitary-Adrenal Axis Parameters 
Blood samples will be obtained for analysis of plasma ACTH, dehydroepiandrosterone sulfate 
(DHEA-S), and serum cortisol at the time points specified in Appendix A .  
6.4.4.1 Plasma ACTH 
Plasma ACTH should be measured  at least twice during Screen ing. ACTH should be measured 
either before, or at least 24 hours after, the DST test. 
6.4.4.2 Plasma DHEA-S 
Plasma DHEA-S should be measured either before, or at least 24 hours after, the DST test. 
6.4.4.3 Fasting Serum Cortisol 
Serum fasting cortisol should be measured along with ACTH either before, or at least 24 hours 
after, the DST test. 
6.4.5 Sit-to-Stand Test 
The sit-to-stand test will be performed at the time points specified in Appendix A . The sit-to-
stand test evaluates the ability of patients to go from standing to sitting in a chair and then getting 
up again with/without the use of their arms or othe r aids. Patients seated in a chair will be asked 
to fold their arms across their chests and to stand up from the seated position once. If they are 
able to successfully rise from the chair, they will be asked to sit down again and then stand up 
and sit down 5 times as quickly as possible.  
The chair should be of standard height so that th e patient‚Äôs legs are in flexion of approximately 
90 degrees about the knee when the feet are flat  on the floor. Patients s hould be advised not to 
place their feet far beneath chair and not to offset the feet in the horizontal plane (i.e., asked to 
place their feet under the front of th e chair, not too far forward [in front of the chair] or too far 
back [under the chair seat]). The same or simila r chair should be used for all measurements. 
The study staff will use a stopwatch to measure th e total time it takes for the patient to stand up 
and sit down 5 consecutive times; start time is in the seated position and stop time is in the final standing position. The total time of the test is m easured. Patients with gait or balance disorders 
are not required to complete the sit-to-stand test. 
6.4.6 Trail-Making Test 
The trail-making test will be performed at the time points specified in Appendix A . The 
trail-making test is a ne uropsychological test of visual attention and task switching that consists 
of 2 parts in which the patient is instructed to  connect a set of 25 dots as quickly as possible 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 60 of 105 while maintaining accuracy. It can provide information about visual search speed, scanning, 
processing speed, and mental flexibilit y, as well as executive functioning.  
The total time of the test is meas ured, with a maximum of 300 seconds. 
6.4.7 Biochemical Markers of Bone Remodeling 
Blood samples for analysis of serum osteocalci n will be obtained from a ll patients at the time 
points specified in Appendix A .  
6.4.8 DXA Scans 
Trabecular bone score, bone mineral density, and body composition (change in the percent and absolute amounts of total body a nd regional fat and lean tissue [whole body, trunk, and leg)] will 
be determined from the DXA scans ( Shepherd et al. 2017 , Athimulam et al. 2019 ) for all 
patients, at the time points specified in Appendix A .  
6.5 Pharmacodynamic Assessments 
Samples for pharmacodynamic (PD) assessments will be collected from all patients at the time points specified in Appendix A .  
6.5.1 Urinary Free Cortisol (UFC) 
The 24-hour UFC with creatinine test will be co llected by the patient at home 2 times during 
Screening only. Each patient will be provided with instructions and supplies to collect all the 
urine produced during a 24-hour period. The 24-hour  urine creatinine level and the total 24-hour 
urine volume will be obtained to confirm complete collection of the urine.  
Test must be performed either before or ¬ïKRXUV DIWHU'67WHVW  
Patients should avoid drinking an unusual amount of fluids ( ¬ï5 L/day) during the 24-hour period. 
Patients should avoid use of any glucocorticoid preparations, incl uding steroid-containing skin or 
hemorrhoid creams, during the collection period. Urinary free cortisol will be measured by 
tandem mass spectrometry. 
6.5.2 Late-Night Salivary Cortisol 
During Screening, two late-night sa livary cortisol samples will be collected, one of which will be 
the night before the Day 1/Baseline Visit. Tests VKRXOGEHSHUIRUPHGHLWKHU EHIRUHRU¬ï  hours 
after, the DST test.  
During treatment with study drug, a la te-night salivary-cor tisol sample should be collected at the 
patient‚Äôs home at bedtime the night before the st udy visit. Patients should be instructed to avoid 
the chewing of licorice or tobacco 60 minutes prior to completing the test.  Complete instructions will be provided to the patient and they will be given supplies for the 
collection of saliva. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 61 of 105 6.5.3 Early-Morning Salivary Cortisol 
Early-morning salivary cortisol will be collected at the site if the patient arrives before 9 am (to 
avoid mix up with the late-night salivary cortisol samples collected by the patient). If the visit is scheduled after 9 am, the sample will be collected at home by the patient the morning of the visit. Early-morning salivary cortisol should be collected either on the same day as the late-night salivary cortisol is collected, or the morning after. 
6.6 Patient-Reported Outcomes 
6.6.1 Cushing QoL Questionnaire 
The Cushing QoL patient questionnaire, which ev aluates the health-related QoL in patients 
with Cushing syndrome ( Webb et al. 2008 ), will be administered to all patients at the time points 
specified in Appendix A . It comprises 12 questions, each with 5 possible answers. The total 
VFRUHUDQJHVIURP‡ØÖ7KH&XVKLQJ4R/LQVWUXPHQWDGGUHVVHVN QRZQSUREOHPDUHDV
associated with Cushing syndrome incl uding trouble sleeping, wound healing/bruising, 
irritability/mood swings/anger, se lf-confidence, physical change s, ability to participate in 
activities, interactions with friends and family, memory issues, and future health concerns 
(Nelson et al. 2013 ). Lower values reflect lower quality of life.  
6.6.2 Beck Depression  Inventory-II 
The Beck Depression Inventory-II (BDI-II), a 21-question self-report inventory that measures depression ( Beck 1996 ), will be completed by all patients at the time points specified in 
Appendix A . Each answer is scored with values 0 to 3. The total score ranges from 0 ‡ØÖ63. 
Scores of 0 ‡ØÖ13 indicate minimal depression, 14 ‡ØÖ19; mild depression; 20 ‡ØÖ28; moderate 
depression; 29 ‡ØÖ63; severe depression. 
6.7 Pharmacokinetic (PK) Assessments 
Intensive PK sampling to assess the plasma concentrations of relacorilant and/or its metabolites will be conducted in all patients at the Week 18 visit ( Appendix A ).  
Pharmacokinetic sampling will take precedence over other procedures when more than 
1 procedure is scheduled for the same time point relative to dosing. 
PK sampling should be performed on the ongoing dose, prior to any dose escalation.  
Acceptable time windows for PK samples are shown in  Table 7 .  
Table 7 Time Windows for Collection of Pharmacokinetic Samples 
Nominal Time Reporting Standards 
Predose Up to 60 minutes before dosing 
1, 2, 4, and 6 hours postdose ¬±10 minutes 
 
Instructions for the collection and handling of the samples will detailed in the laboratory manual.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 62 of 105 Drug concentration information that would unblind the study will not be repor ted to investigative 
sites or blinded personnel. 
6.8 Pharmacodynamic/Biomarker Assessments 
Blood samples will be obtained from all patients for analysis of mRNA expression of 
glucocorticoid-modulated ge nes and proteins at the time points specified in Appendix A . Test 
PXVWEHSHUIRUPHG HLWKHU EHIRUHRU¬ïKRXUVDIWHU'67WHVW . The results of these assessments 
will remain blinded. 
6.9 Appropriateness of the Measures 
The assessments to be used in this study are standard for evaluation of patients with Cushing 
syndrome and are generally recognized as  reliable, accurate, and relevant.  
6.10 Blood Storage 
A portion of the blood drawn predose at all visits (except the Screening Visit, Follow-up Visit, ET, and Unscheduled Visits) will be frozen and stored. For additional information on sample 
retention, see Section  11.5. These stored blood samples may be used by the Sponsor for retesting 
safety laboratory parameters, for measurement of  study drug and/or concom itant drug levels in 
the blood, or for clinical laboratory testing to provide additional safety data. No human genetic 
testing will be performed without e xpressed consent of  study patients. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 63 of 105 7 STUDY ASSESSMENTS AND PROCEDURES BY STUDY VISIT 
A Summary of Activities (SOA) is provided in Appendix A. Most assessments are for all 
patients; a few are performed only in patients in a specific subgroup (i.e., the impaired glucose 
tolerance/diabetes subgroup or the uncontrolled hypertension subgroup). 
In the event that a patient is unable to come to the clinic to participate in study-related visits or 
procedures, Sponsor-approved altern ative options may be provided to  the Investigator sites based 
on the needs and safety of patients. This ma y include the provision of study-drug dispensation 
and delivery outside  of the clinic. 
Any deviation from protocol procedures will be noted in the patient‚Äôs clinical chart and eCRF 
and reported to the IRB/EC as applicable. In a ddition, the Sponsor will be  promptly notified of 
any protocol deviations. Though alternative methods for safety  and study assessments (i.e., 
phone contact, virtual study visits , use of alternative locations for assessment, including local 
labs or imaging centers, etc.) are permitted due to the COVID-19 pandemic, any modified protocol-described processes should be  recorded as protocol deviations. 
7.1 Scheduled Visits 
The window for each study visit is relative to th e Baseline Visit. The acceptable visit window is 
¬±7 days for all visits (except for the Week 22 and ET visits, in which case a 3-week visit window 
[2 weeks before the scheduled visit, 1 week afte r the scheduled visit] and 2-week [2 weeks after 
the scheduled visit] visit wi ndow, respectively, is permitted). 
Patients will remain on st udy treatment post Week 22 visit until it has been confirmed that all 
results for efficacy assessment have been re ceived and no repeat asse ssments are required. The 
follow-up visit must occur 28 days af ter the last dose of study drug. 
With regard to sequence of tests and acceptable time windows: 
x Predose procedures must be  completed before dosing and, where applicable, before 
breakfast. 
x Dosing will take place after completi on of all predose procedures.  
x All clinical laboratory samples and the predose PK samples will be collected when the 
patient is fasting (at least 4 hours). 
x Measurement of vital signs and ECG record ings should be avoided within 15 minutes 
after venipuncture or cannulation and, therefor e, will normally be performed before blood 
sampling.  
x At all visits beginning with Week 2, study drug should be taken in the clinic during the 
visit and after initial blood draws. 
x At every visit during dose escalation (Week 2+) and maintenance phase (Week 14+), 
blood chemistry including potassium concentr ations are checked, blood pressure is 
measured, and physical examination (incl uding checking for edema) is conducted. 
Investigators are required to report adve rse events to the Sponsor promptly. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 64 of 105 x Pharmacokinetic sampling (at Week 18) will take precedence over other procedures when 
more than 1 procedure is scheduled for the same time point relative to dosing. Acceptable 
time windows for PK samples are: 
Within 1 hour before dosing for the predose sample, and ¬±10 minutes for  
the 1-, 2-, 4-, and 6-hour  postdose samples.  
x Ambulatory BP monitoring will be initiated in  the clinic after all blood samples are 
obtained with the exception of the Week 22 Visit where the ABPM should be performed within 7 days prior to the visit. 
x Study-drug dosing should occur after comple tion of the 2-hour oGTT (except for 
Week 18, when oGTT may take place after dosing for logistical issues due to intensive 
PK sampling that would prolong patient stay).  
x Acceptable time windows for oGTT samples are: 
¬±10 minutes for the 0.5-, 1-, 1.5-, and 2-hour samples 
x Electrocardiogram recording should be performed 2 hours ¬±30 minutes after study-drug dosing. 
If a patient discontinues early from the study, the pa tient will complete an early termination (ET) 
visit at the time of last dose of study drug or within 2 weeks. They will be instructed to return to 
the site for the Week 22 visit per their origin al dosing schedule, and for the follow-up visit 28 
days after the last dose of study drug. Depending on the timing of the patient‚Äôs discontinuation, 
the visits may happen out of sequenc e, and either visit may serve as the patient‚Äôs last study visit.  
The Investigator may repeat tests in the even t of a technical failure  and/or if additional 
observations or samples of blood are needed to  monitor patient safety; these will not be 
considered protocol deviations. 
The required procedures for each study visit ar e outlined in the study Schedule of Clinical 
Assessments and Procedures  in Appendix A .  
7.1.1 6FUHHQLQJ9LVLW√≠WR √≠GD\  
The purpose of the Screening visit/period is to ensure that appropriate patients are entered into 
the study and that they remain stable during the pretreatment period.  
x Obtain written informed consent prior to performing any study procedures  
x Review inclusion/exclusion criteria 
x Complete medical history a nd review of medications 
x Collect demographic and baseline diseas e characteristics information, including 
confirmation of me dication washout 
x Perform a complete physical examinati on, including height, weight, and waist 
circumference 
x 12-lead ECG (in duplicate) 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 65 of 105 x Measure vital signs 
x Review concomitant medications  
x Draw blood samples for laboratory tests 
 Serum pregnancy test (women of childbearing potential only). 
 Chemistry and hematology 
 GR-activity biomarker test 
 2-hour oGTT (after an 8-hour fast); VKRXOGEHFROOHFWHG¬ïZHHNVDIWHU an increase in 
diabetes medication must be performed with in 2 weeks of the Baseline Visit and used 
as Baseline 
 HbA1c (should be collected ¬ï weeks after an increase in diabetes medication); must 
be performed within 2 weeks of the Baseline Visit and used as Baseline 
 HPA-axis parameters 
x Thyroid-function tests 
x 24-hour UFC with creatinine (collected by the patient at home twice during Screening).  
x DST with dexamethasone leve ls. 1-mg overnight or 2 day low-dose dexamethasone 
suppression test must be performed during Screening. Dexamethasone levels must be 
measured concurrently. Estrogen prepara tions, including birth control and hormone 
replacement treatments, should be held for a duration of at least 5 half-lives of the 
estrogen analogue prior to DST. 
x Late-night salivary cortisol (collected by the patient at home at l east twice on different 
nights during Screening), one of which will be the night before the Day 1/Baseline Visit).  
x Early-morning salivary cortisol (collected at th e site if the patient arrives before 9 am); 
should be collected either on the same day as the late-night salivary cortisol is collected, 
or the morning after. 
x ABPM (24-hour) test will be a ssessed for all patients during Screening. For patients with 
an increase to their anti-hypertension medi cations either before  or during Screening, 
ABPM VKRXOGEHSHUIRUPHG¬ïZHHNVDIWHUWKH increase. During Screening, ABPM 
VKRXOGEHSHUIRUPHGH LWKHUEHIRUHRU¬ïK ours after, the DST test; must be performed 
within 2 weeks of the Baseline Visit and used as Baseline. 
x Schedule next visit. 
Patients who fail Screening may be rescreened (see Section  4.3).  
7.1.2 Baseline Visit (Day 1) 
x Review inclusion/exclusion criteria 
x Complete medical history a nd review of medications 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 66 of 105 x Collect demographic and baseline diseas e characteristics information, including 
confirmation of me dication washout 
x Perform a complete physical examination, including, weight, and waist circumference 
x Measure vital signs 
x Review concomitant medications  
x Urine pregnancy test (women of childbearing potential only) 
x Draw blood samples for laboratory tests 
 Chemistry and hematology 
 Lipid-metabolism panel (fasting) 
 Coagulation panel 
 Serum osteocalcin 
 2-hour oGTT, including measurement of glucag on levels (after an 8-hour fast and 
used as Baseline‚Äîunless performed within 2 weeks of the Baseline Visit; glucagon 
levels will be assessed only for patients with DM/IGT) 
 HbA1c (used for Baseline‚Äîunless collected within 2 weeks of the Baseline Visit) 
x Early-morning salivary cortisol (collected at the site if the patient arrives before 9 am) 
x Cushing QoL questionnaire 
x Beck Depression Inventory 
x Sit-to-stand test 
x Trail-making test 
x DXA scan (¬±2 weeks of the Baseline Visit); patients to get DXA scan before Baseline 
Visit only in the case they are already determined to qualify for the study 
x Dosing diary 
x Study-drug dispensing and/or adherence 
x Query for AEs 
x Schedule next visit  
7.1.3 Week 2 (¬±7 days) 
x Perform a complete physical examination, including, weight, and waist circumference 
x Measure vital signs 
x Query for AEs 
x Review concomitant medications 
x Urine pregnancy test (women of childbearing potential only) 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 67 of 105 x Draw blood samples for laboratory tests 
 Chemistry and hematology 
 2-hour oGTT (after an 8-hour fast; for DM/IGT patients only) 
x ABPM (24-hour) test (for hypertension patients only) 
x Dosing diary 
x Study-drug dispensing and/or adherence 
x Schedule next visit 
7.1.4 Week 6 (¬±7 days) 
x Perform a complete physical examination, including, weight, and waist circumference 
x Measure vital signs 
x Query for AEs 
x Review concomitant medications 
x Urine pregnancy test (women of childbearing potential only) 
x Draw blood samples for laboratory tests  Chemistry and hematology 
 GR-activity biomarker test 
 2-hour oGTT (after an 8-hour fast; for patients with DM/IGT at Baseline) 
 HPA-axis parameters  
x Late-night salivary cortisol (collected at the patient‚Äôs home at bedtime the night before 
the study visit) 
x Early-morning salivary cortisol (collected at the site if the patient arrives before 9 am) 
x ABPM (24-hour) test (for patients with  systolic hypertension at Baseline) 
x Cushing QoL questionnaire 
x Beck Depression Inventory 
x Sit-to-stand test 
x Trail-making test 
x Dosing diary 
x Study-drug dispensing and/or adherence 
x Schedule next visit  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 68 of 105 7.1.5 Week 10 (¬±7 days) 
x Perform a complete physical examination, including, weight, and waist circumference 
x Measure vital signs 
x Query for AEs 
x Review concomitant medications 
x Urine pregnancy test (women of childbearing potential only) 
x Draw blood samples for laboratory tests 
 Chemistry and hematology 
 GR-activity biomarker test 
 2-hour oGTT, including measurement of glucagon levels (after an 8-hour fast; for all 
patients; glucagon levels  will be assessed only fo r patients with DM/IGT) 
 HbA1c (for all patients) 
 HPA-axis parameters 
x Late-night salivary cortisol (collected at the patient‚Äôs home at bedtime the night before 
the study visit) 
x Early-morning salivary cortisol (collected at the site if the patient arrives before 9 am) 
x ABPM (24-hour) test (for all patients) 
x Cushing QoL questionnaire 
x Beck Depression Inventory 
x Sit-to-stand test 
x Trail-making test 
x Dosing diary 
x Study-drug dispensing and/or adherence 
x Schedule next visit  
7.1.6 Week 14 (¬±7 days) 
x Perform a complete physical examination, including, weight, and waist circumference 
x Measure vital signs 
x Query for AEs 
x Review concomitant medications 
x Urine pregnancy test (women of childbearing potential only) 
x 12-lead ECG (in duplicate) 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 69 of 105 x Draw blood samples for laboratory tests 
 Chemistry and hematology 
 Coagulation panel 
 GR-activity biomarker test 
 2-hour oGTT (after an 8-hour fast; for patients with DM/IGT at Baseline) 
 HPA-axis parameters  
x Late-night salivary cortisol (collected at the patient‚Äôs home at bedtime the night before 
the study visit) 
x Early-morning salivary cortisol (collected at the site if the patient arrives before 9 am) 
x ABPM (24-hour) test (for patients with  systolic hypertension at Baseline). 
x Cushing QoL questionnaire 
x Beck Depression Inventory 
x Sit-to-stand test 
x Trail-making test 
x Dosing diary 
x Study-drug dispensing and/or adherence 
x Schedule next visit 
7.1.7 Week 18 (¬±7 days) 
x Perform a complete physical examination, including, weight, and waist circumference 
x Measure vital signs 
x Query for AEs 
x Review concomitant medications 
x Urine pregnancy test (women of childbearing potential only) 
x Draw blood samples for laboratory tests 
 Chemistry and hematology 
 2-hour oGTT (after an 8-hour fast; for patients with DM/IGT at Baseline) 
 Intensive PK sampling 
x Early-morning salivary cortisol (collected at the site if the patient arrives before 9 am) 
x ABPM (24-hour) test (for patients with  systolic hypertension at Baseline) 
x Cushing QoL questionnaire 
x Beck Depression Inventory 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 70 of 105 x Sit-to-stand test 
x Trail-making test 
x Dosing diary 
x Study-drug dispensing and/or adherence 
x Schedule next visit 
7.1.8 Week 22 (-14/+7 days) 
x A 3-week visit window (2 weeks before the sc heduled visit, 1 week after the scheduled 
visit) is permitted. 
x Perform a complete physical examination, including, weight, and waist circumference 
x Measure vital signs 
x Query for AEs 
x Review concomitant medications 
x 12-lead ECG (in duplicate) 
x Urine pregnancy test (women of childbearing potential only) 
x Draw blood samples for laboratory tests 
 Chemistry and hematology 
 Lipid-metabolism panel (fasting) 
 Coagulation panel 
 Serum osteocalcin 
 GR-activity biomarker test  
 2-hour oGTT, including measurement of glucagon levels (after an 8-hour fast; for all 
patients; glucagon levels  will be assessed only fo r patients with DM/IGT) 
 HbA1c (for all patients) 
 HPA-axis parameters 
x Late-night salivary cortisol 
x Early-morning salivary cortisol (collected at the site if the patient arrives before 9 am) 
x ABPM (24-hour) test (for all patients), performed within 7 days prior to Week 22 Visit 
x Cushing QoL questionnaire 
x Beck Depression Inventory 
x Sit-to-stand test 
x Trail-making test 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 71 of 105 x DXA scan 
x Study-drug dispensing* and drug adherence 
x Schedule next visit  
* Patients will remain on study treatment until it has been confir med that all results for efficacy 
assessment have been received and no repeat assessments are required. 
7.1.9 Early-Termination Visit (+14 days) 
If the patient discontinues study drug prior to Week 22, the patient will be encouraged to 
complete the following assessments at the time of last dose of study drug or within 2 weeks. 
They will be instructed to return to the site  for the Week 22 visit per their original dosing 
schedule, and for the follow-up visit 28 days after the last dose of study drug. 
x Perform a complete physical examination, including, weight, and waist circumference 
x Measure vital signs 
x Query for AEs 
x Review concomitant medications 
x 12-lead ECG (in duplicate) 
x Urine pregnancy test (women of childbearing potential only) 
x Draw blood samples for laboratory tests 
 Chemistry and hematology 
 Lipid-metabolism panel (fasting) 
 Coagulation panel 
 Serum osteocalcin 
 GR-activity biomarker test 
 2-hour oGTT, including measurement of glucagon levels (after an 8-hour fast; for all 
patients; glucagon levels  will be assessed only fo r patients with DM/IGT) 
 HbA1c (for all patients) 
 HPA-axis parameters 
x Late-night salivary cortisol 
x Early-morning salivary cortisol (collected at the site if the patient arrives before 9 am) 
x ABPM (24-hour) test (for all patients)  
x Cushing QoL questionnaire  
x Beck Depression Inventory 
x Sit-to-stand test 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 72 of 105 x Trail-making test 
x DXA scan (should not be repeated if it was already completed within 8 weeks prior to ET 
Visit; acceptable visit window is up to  3 months following ET Visit). 
x Study-drug adherence 
x Schedule next visit  
7.1.10 Follow-Up Visit (¬±7 days) 
x Perform a complete physical examination, including, weight, and waist circumference 
x Measure vital signs 
x Query for AEs 
x Review concomitant medications 
x Urine pregnancy test (women of childbearing potential only) 
x Draw blood samples for laboratory tests 
 Chemistry and hematology 
x Study-drug adherence 
7.2 Unscheduled Visits 
As appropriate, assessments deem ed clinically necessary by the Investigator may be done at 
unscheduled visits. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 73 of 105 8 SAFETY EVENT DOCUMENTATION AND REPORTING 
8.1 Investigator‚Äôs Responsibilities 
Investigators are responsible for monitoring the safety of patients who have entered this study 
and for providing appropriate me dical care. By exercising appropriate healthcare options, the 
Investigator remains responsible for managing AEs. All SAEs must be  reported to Sponsor 
within 24 hours from awareness of the event.  
The Investigator (or medically qua lified designee) is re sponsible for determining whether an AE 
is clinically significant for the patient. Clinical significance will be documented in the patient‚Äôs 
medical records with the AE information. 
Safety results collected during the study (e.g., AEs,  laboratory test results, physical findings) will 
be monitored on an ongoing basis by the Medical  Monitor and Investigator. Sponsor or its 
designee will promptly evaluate  all reported safety inform ation against cumulative product 
experience to identify and expeditiously co mmunicate possible new safety findings to 
Investigators and applicable regulatory authorities.  
8.2 Definition of an  Adverse Event 
An AE is any untoward medical occurrence in  a study patient administered a pharmaceutical 
product that does not necessarily ha ve to have a causal relations hip with the treatment. An AE 
can, therefore, be any unfavorable and unint ended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associat ed with the use of any study drug that emerges 
or worsens relative to the patient‚Äôs pretreatment baseline, regardless of whether it is related to the 
study drug.  
8.3 Definition of a Serious Adverse Event 
An SAE is any AE resulting in any of the following outcomes: 
x Death (i.e., the AE caused or led to the fatality) 
x Life-threatening AE (i.e., the AE refers to an  event in which the patient was at risk of 
death at the time of the event; it does not refe r to an event that hypothetically might have 
caused death if it were more severe) 
x Hospitalization or prolongation of existing hospitalization (i.e., hospitalizations for 
scheduled treatments and elective medica l/surgical procedures are not SAEs by 
this criterion) 
x Persistent or significant disability/incapacity (i.e., the AE results in substantial reduction 
of the patient‚Äôs ability to perform activities of daily living) 
x Congenital anomaly or birth defe ct (i.e., an adverse finding in a child or fetus of a patient 
exposed to the study medication before  conception or during pregnancy)  
x Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered seri ous when, based upon appropriate medical 
judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes lis ted in this definition. Examples of such 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 74 of 105 medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscras ias or convulsions that do not result in 
inpatient hospitalization, or  the development of drug dependency or drug abuse 
(21 CFR 312.32). 
8.4 Expectedness 
A serious AE is considered unexpected if not reported in the Investigator‚Äôs Brochure or if the 
event is of greater severity or frequency than de scribed in the Investigator‚Äôs Brochure, (i.e., not 
specified in the RSI section of the Investigator‚Äôs Brochure). 
8.5 Clinical-Laborator y Adverse Events 
All out-of-range laboratory values w ill be determined to be  clinically significant or not clinically 
significant by the Investigator. An abnormal labor atory value that meets any of the following 
criteria will be recorded as an AE on the eCRF:  
x Leads to a dose modification or patient withdrawal from the study. 
x Is accompanied by clinical symptoms. 
x Requires a change in co ncomitant medications.  
Other clinically significant laboratory values may be reported as  AEs at the discretion of the 
Investigator.  
Patients with a clinically significant out-of-range laboratory value will be followed until the 
laboratory value returns to normal, the value beco mes medically stable, or the patient is deemed 
by the Principal Investigator to be lost to fo llow-up. The Investigator will treat the patient as 
medically required at appropriate intervals until this occurs. 
8.6 Documentation of Adverse Events 
Patients will be evaluate d and questioned to identify AEs during the study.  
Collection of AEs will start immediately following signing of the ICF and will continue 
throughout the study. All AEs will be documented on the patient‚Äôs medical record and AEs for 
all the randomized patients will be documented in the eCRF. 
Illnesses present before the patient signs the in formed consent form (ICF) are considered pre-
existing conditions and are documented on the medi cal history eCRF. Preexisting conditions that 
worsen during the study are entered on the AE eCRF. AEs that occur after start of study 
treatment and up to and including 28 days after administration of the last dose of study drug will 
be considered TEAEs. Any AEs reported more than  28 days after the last dose of study drug will 
be considered posttreatment AEs and do not need to be reported to Corcept, unless the event 
meets the definition of serious (see  Section 8.3 ) and the relationship to the study drug is possibly 
related, probably rela ted, or related (see Section  8.7.2). In such cases, these posttreatment SAEs 
need to be reported per the process in Section  8.8 and are not to be entered in eCRF. The 
Investigator will treat the patient as medically required until the AE either resolves or becomes medically stable. This treatment  may extend beyond the duration of the study. The Investigator 
will record treatment and medications required for treatment on the appropriate eCRF(s). 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 75 of 105 In the event that a patient is withdrawn from the study because of an AE, the event must be 
recorded on the Termination eCRF as the reason for discontinuation. 
All AEs that are drug-related and unexpected (not specified in the RSI section of the 
Investigator‚Äôs Brochure) or if the event is of great er severity or frequency than that described in 
the Investigator‚Äôs Brochure) must be repor ted to the governing IRB/Independent Ethics 
Committee (IEC)/Health Authorities as required.  
8.7 Adverse Event Classification 
8.7.1 Intensity Grades of  Adverse Events 
Seriousness of an AE is not synonymous with severity. To describe the maximum severity of the 
AE on the AE eCRF, the Investigator will use the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Ev ents (NCI-CTCAE), version 5.0 ( NCI-CTCAE 2017 ). For 
events not listed in the NCI-CTCAE, the definitions from the NCI-CTCAE provided in Table 8  
should be used to evaluate the grade of severity for the AE.  
Table 8 AE Grades Based on the Common Terminology Criteria for Adverse Events 
Grade Description 
1 Mild : asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not 
indicated  
2 Moderate : minimal, local, or noninvasive intervention indicated; limiting age-appropriate 
instrumental activities of daily livin g (e.g., preparing meals, shopping for groceries or clothes, using 
the telephone, and managing money)  
3 Severe: severe or medically significant but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling;  limiting self-care activities of daily living (e.g., 
bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden)  
4 Life-threatening : Life-threatening consequences; urgent intervention indicated  
5 Death : Death related to AE  
Source: National Cancer Institute (N CI) Common Terminology Criteria for Adve rse Events (CTCAE), version 5.0 
(NCI-CTCAE 2017 ). 
8.7.2 Relationship of Adv erse Event to Study Drug or Procedure 
The Investigator responsible for the patient‚Äôs car e (or qualified designee) will assess causality of 
AEs and SAEs based on the causal attribution guidance in Table 9 . The Investigator‚Äôs 
assessment of causality must  be provided for all AEs (serious and nonserious).  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 76 of 105 Table 9 Causal Attribution Guidance for AEs 
Not related to study drug  An AE that is judged to be clearly due only to extraneous causes such as 
diseases, environment, and the like or for which it is temporally 
implausible to be related to use of the study drug. The cause must be noted on the AE eCRF. 
Possibly related to study drug An AE that might be due to the use of the drug. The relationship in time is 
reasonable; therefore, a causal relationship cannot be excluded. An alternative explanation is inconclusive, e.g., concomitant drug(s), concurrent disease(s). 
Probably related to study drug An AE that might be due to the use of the drug. The relationship in time is 
suggestive. An alternative explanation is less likely, e.g., concomitant drug(s) or concurrent disease(s). 
Related to study drug An AE that is due to the use of the drug.  
8.8 Procedures for Reporting a Serious Adverse Event 
Any SAE occurring from the time of informed consent and for 28 days after the last dose of 
study drug must be reported immediately (latest within 24 hours) to the pharmacovigilance vendor by completing and submitting the SAE form to the contact specified on the SAE form. 
All patients with an SAE must be followed and the outcomes repo rted. The Investigator must 
supply the Sponsor and the IRB/IEC with any additional requested information.  
8.9 Disease-Related Events and/or Disease- Related Outcomes Not Qualifying as 
AEs or SAEs 
Not applicable.  
8.10 Adverse Event Follow-Up 
All AEs considered to be related to study drug (see Section  8.7.2) and all SAEs will be followed 
until resolution, until deemed stable by the Invest igator, or until the patient is deemed by the 
Principal Investigator to be lost to follow-up. 8.11 Pregnancy 
All pregnancies a nd outcomes of pregnancy should be re ported to the Sponsor during the study 
and within 28 days of the last dose of study treatment. 
8.11.1 Maternal Exposure 
If a patient becomes pregnant during the study, study treatment s hould be discontinued 
immediately. Pregnancy itself is not regarded as an AE.  
If any pregnancy occurs during the study or with in 28 days of the final dose of the study drug, 
the Investigator or designee should inform the appropriate Sponsor repr esentatives immediately 
but no later than 24 hours of when he or she becomes aware of it. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 77 of 105 The Investigator or designee should ensure that  all relevant informa tion is provided to the 
responsible Clinical Safety Group. All outcome s of pregnancy must be reported by the 
Investigator within 24 hours after he or she becomes aware of it. 
Congenital abnormalitie s/birth defects and spontaneous mis carriages should be reported and 
handled as SAEs. Elective abortions without comp lications should not be handled as AEs. The 
outcome of all pregnancies (spontaneous miscarri age, elective termination, ectopic pregnancy, 
normal birth or congenita l abnormality) should be followed and documented even if the patient 
has discontinued the study. 
8.11.2 Paternal Exposure 
Pregnancy of the pa tient‚Äôs partner is not considered to be an AE; however, the outcome of all 
pregnancies (spontaneous miscarriage, elective termination, ectopic pre gnancy, normal birth or 
congenital abnorma lity) will, if possible, be followed a nd documented. To capture information 
about a pregnancy from the partner of a male pa tient, the Investigator or designee must first 
obtain the consent of the male pa tient‚Äôs partner; the male patient  should not be asked to provide 
this information. A consent form specific to th is situation must be us ed. The outcome of any 
conception occurring from the date of the first dose until 28 days after dosing should be followed 
and documented. 
8.12 Treatment of Overdose 
There is currently no experience with over dose of study drug. For monitoring symptoms of 
excessive GR antagonism, refer to Section  5.4.1. If clinically significant GR antagonism is 
suspected, dexamethasone may be administered. 
Decisions regarding dose interruptions or modifications will be made by the Investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the patient. 
8.13 Emergency Sponsor Contact 
In a medical emergency (i.e., an event requiring i mmediate attention regard ing the treatment of a 
patient, operation of the clini cal study, and/or the use of st udy drug), study site personnel will 
apply appropriate medical intervention according to current standards of care and contact the Medical Monitor listed on the cover page. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 78 of 105 9 STATISTICAL METHODS 
9.1 Analysis Populations 
The analysis populations are defined in Table 10 .  
Table 10 Definitions of Analysis Populations 
Population Description 
Safety All patients randomly assigned to study treatment and who take ¬ï1 dose of 
study treatment. Patients will be analyzed according to the treatment they 
actually received. 
Intent-to-treat (ITT) a The ITT population will include all patients who were randomized to receive relacorilant or placebo, even if they do not receive any study treatment. This 
population will be used for the analysis of the primary and secondary efficacy endpoints.  
Modified intent-to-treat (mITT)  The mITT population will include all patients in WKH,77 SRSXODWLRQ ZLWK ¬ï
post-randomization efficacy assessment for the primary and secondary 
efficacy endpoints of ABPM and/or AUC glucose . This population will be used 
for sensitivity analyses performed on the primary and secondary efficacy endpoints.  
PK The subset of the Safety population with adequate PK data. 
PD The subset of the Safety population with adequate PD data. 
a. Analyses of blood-pressure control measures will be  performed on all patients in the ITT population with 
hypertension, regardless of whether they have DM/IGT at Baseline. Analyses of measures of glycemic control 
will be performed on all patients in the ITT population with DM/IGT, regardless of whether they have hypertension at Baseline. 
9.2 General Statistical Considerations 
The statistical analysis will be conducted by the S ponsor and/or its designe e. Statistical methods 
will be prespecified and documented in detail in a statistical analysis plan, to be finalized before 
study unblinding. 
All continuous variables will be summarized using descriptive st atistics (number of patients, 
means, percentiles, standard deviations) and confidence intervals (CIs) for values measured at 
each visit, as well as changes from Baseline. For categorical variables, counts, percentages, and 
their 95% CIs will be presented for each visit. 
Predose measurements on Day 1 will be considered the baseline values. If a Day 1 predose value 
is not available, the Screening measurement may be used as the baseline value.  
9.3 Hypothesis Testing 
For the testing of the primary and certain secondary efficacy endpoints, adjustment for 
multiplicity will be implemented to maintain a 2-sided 0.05 significance level for the Family-
Wise type I error rate.  
In order to provide strong control of the Type I error, certain secondary analyses will be tested 
using a gated testing approach at a 2-sided alpha  level of 0.05. If the null hypothesis is rejected 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 80 of 105 Seventy-eight patients with hypert ension (39 per treatment group) will ensure at least 90% power 
to detect a difference between placebo and treatment arms in average SBP of 7 mm Hg (based on 
ABPM). These calculations assume a common standard deviation of 8 mm Hg and a 0.025 
two-sided significance level two- sample t-test. Twenty-eight percent dropout rate from Baseline 
to Week 22 is assumed in this calculation. 
In summary, the expected randomization of 130 patients in the study w ill result in 78 patients 
within each of the DM/IGT and hypertension subgr oups. This sample size will provide sufficient 
power to detect the target differences in th e primary endpoint for each of the subgroups.  
9.5 Analysis Plan 
9.5.1 Patient Disposition 
The numbers of patients who were enrolled, and who were randomized along with the reasons 
for withdrawal will be su mmarized by treatment group. 
9.5.2 Demographic and Baseline  Characteristics Data 
Demographics and baseline ch aracteristics will be summarized for the Safety Population, 
ITT, and mITT populations. The summaries will include frequencies and percentages for 
categorical variables, and mean, standard deviation, median, minimum, and maximum for 
continuous variables.  
These summaries will include patient medical history, including the diagnosis, etiology, and 
treatment history of adrenal adenomas/hyperplasia. 
9.5.3 Prior and Concomitant Medications 
A list of all medications for diabetes, hyperten sion, or Cushing-syndrom e‚Äìrelated comorbidities 
used at Baseline and over the course of the study will be generated. 9.5.4 Analysis of Efficacy Endpoints 
9.5.4.1 Analysis of Primary Efficacy Endpoint 
The primary endpoint is defined in Section  3.2.1. 
For the hypertension subgroup of the ITT Populat ion, the estimand of interest is the between-
treatment difference in change in average SB P based on 24-hour ABPM from Randomization to 
Week 22 (estimated using a MMRM model) regardless of treatment discon tinuation and as if 
rescue medication was not available. For the pr imary analysis, missing values at Week 22 for 
patients who use rescue medication or discontinue treatment early, will be imputed using a 
placebo wash-out multiple imputation. For thos e patients who use rescue medication for 
hypertension after randomization and before Visit Week  22, the values collected after first use of 
rescue medication are irrelevant to  the clinical question of interest  and will not be used in the 
analysis. For patients who discontinue treatment early, all collect ed values (including retrieved 
drop-outs) will be used in the analysis. Additional details are provided in the SAP.The primary efficacy analysis for the primary endpoint of change in 24- hour average SBP from Randomization to Week 22 will be performed usi ng a linear mixed-model-f or-repeated-measures 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 81 of 105 (MMRM) using data with th e imputation method described above. Restricted maximum 
likelihood (REML) estimation will be used. The MMRM model will include Baseline average 
SBP based on 24-hour ABPM as a covariate; treatme nt, visit, and treatment by visit interaction, 
and stratification factor as fixe d effects; patients within treatme nt groups as random effects. In 
the hypertension subgroup, the stratification factor  at randomization identif ies patients with or 
without DM/IGT. An unstructured covariance stru cture will be used to model within-patient 
error, and the Kenward Roger approximation will be used to model denominator degrees of 
freedom. 
The primary analysis will determine whether there is a difference between treatment groups in 
terms of change in 24-hour average SBP from Randomization to Week 22. This will be 
accomplished by using appropriate linear contrasts of the parameters in the MMRM model described above. 
 Additional sensitivity and supplemental analys es for the primary endpoint, including subgroups 
of interest, will be specified in the SAP. 
9.5.4.2 Analysis of Secondary Efficacy Endpoints 
The secondary efficacy endpoints are defined in Section  3.2.2. 
For continuous endpoints in the study, the anal ysis will be performed using a linear MMRM 
model. Restricted maximum likelihood (REM L) estimation will be used. The MMRM model 
will include Baseline value (for the respective endpoint) as a covariate; treatment, visit, treatment 
by visit interaction, and stratifica tion factor (at randomization) as fixed effects; and patients 
within treatment groups as random effects. An un structured covariance stru cture will be used to 
model within-patient error, and the Kenward-Roger approximation will be used to model denominator degrees of freedom. 
The analysis for each of the endpoints will dete rmine whether there is a difference between 
treatment groups in terms of change from Randomization to Week  22. This will be accomplished 
by using appropriate linear cont rasts of the parameters in the MMRM model described above. 
Additional details will be described in the SAP. For endpoints described as proportions in the study, the point estimate and the 2-sided 95% CI 
will be calculated. A logistic m odel including effects for treatment, continuous baseline value, 
and stratification factor at ra ndomization will be used to assess differences in proportions 
between treatment arms ( Steingrimsson et al. 2017 ).  
9.5.4.3 Analysis of Exploratory Endpoints 
The Exploratory Endpoints listed in Section  3.2.3 will be analyzed using methods similar to the 
analyses of primary and secondary endpoints if they are measured repeatedly over the course of the study. Detailed analysis methods will be described in SAP. 
9.5.5 Safety Analyses 
Safety variables will be analyzed for the Safety Population, define d as all patients who received 
¬ïGRVHRIVWXG\GUXJ  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 82 of 105 TEAEs will be summarized by treatment group. Serious AEs and TEAEs that lead to 
study-drug withdrawal or withdrawal from the study will be summa rized by treatment 
group and listed by patient. 
TEAEs will be summarized by treatment, as applicable, and displayed using the Medical 
Dictionary for Regulatory Activities (MedDRA) system organ class and preferred term, as well 
as by intensity and relationship to the study drug.  
Clinical laboratory test resu lts (chemistry and hematology), vital sign measurements, and 
ECG interval results will be summarized as changes from baseline by parameter and visit 
using descriptive statistics. Shift tables will describe changes from Baseline in clinical laboratory values. 
9.5.6 PK Analysis 
The details of the PK analysis will be outlined in a separate document. 
9.5.7 PD Analysis 
Analysis of PD endpoints will be described in a separate PD anal ysis plan finalized before study 
unblinding.  
9.5.8 Biomarker/Pharmaco genetic Analysis 
Biomarker and pharmacogenetic exploratory analyses will be described in the SAP finalized 
before study unblinding. 
9.5.9 Interim Analysis 
Not applicable.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 83 of 105 10 ETHICAL AND LEGAL CONSIDERATIONS 
10.1 Compliance with IRB/IEC Regulations 
This study is to be conducted in accordance w ith IRB regulations (U S 21 CFR Part 56.103), IEC 
regulations, or applicable local regulations. The protocol, info rmed consent form(s) (ICFs), 
recruitment materials, and all patient materials will be submitted to the IRB/IEC for review and 
approval. Approval of both th e protocol and the consent form  must be obtained before any 
patient is enrolled, and the Inve stigator must submit written a pproval to the Sponsor before 
enrolling any patient. The Investigator is re sponsible for informing the IRB/IEC of any 
amendment to the protocol in accordance with local requirements. The protocol must be re-approved by the IRB/IEC on receipt of amendments  and annually, as local regulations require. 
The investigators should not imple ment any deviation form, or ch anges to, the protocol without 
agreement by Corcept and documented approval from IRB/IEC, except where necessary to 
eliminate an immediate hazard( s) to trial subjects.  
All changes to the consent form must be approved by the IRB/IEC; a determination will be made regarding whether previously consented patients need to be re-consented.  
The Sponsor or their designee is to be notified immediately if the responsible IRB/IEC has been 
disqualified or if proceedings leading to disqualification have begun. C opies of all IRB/IEC 
correspondence with the Investigator should be provided to the Sponsor or their designee. Progress reports and notifications of serious adverse drug reactions will be provided to the 
IRB/IEC according to local regulations and guidelines. 
10.2 Ethical Conduct of the Study 
The study will be performed in accordance with ethi cal principles that have their origin in the 
Declaration of Helsinki and are consistent  with ICH/GCP and applicable regulatory 
requirements. 
The Investigator will ensure that the study proced ures outlined in this pr otocol will be conducted 
in accordance with applicable country and local regulations. 
10.3 Protection of Human Patients 
10.3.1 Compliance with Informed -Consent Regulations  
Written informed consent is to be obtained from each patient and/or from the patient‚Äôs legally 
authorized representative prior to enrollment into the study or conducting any study procedures. 
The Investigator(s) at each center will ensure that  each patient is given full and adequate oral and 
written information about the na ture, purpose, possible risk, a nd benefit of the study. Patients 
must also be notified that they are free to di scontinue from the study at  any time. The patient 
should be given the opportunity to ask questions and allowed time to consider the information 
provided. The Informed Consent process discussi on should be documented in patient‚Äôs record. 
The patient‚Äôs signed and dated ICF must be obtained before conducting any study procedures. 
The Principal Investigator(s) must maintain the original, signed ICF. A copy of the signed ICF 
must be given to the patient. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 84 of 105 The ICF will contain all of the elements required by ICH guidelines for GCP and any additional 
elements required by local regulations. 
The ICF should include information about the possible retention of biological samples at the 
conclusion of this study. With  the patient‚Äôs permission: 
x Samples, including blood, plasma, serum and ti ssue samples, may be retained for future 
analysis to help identify biomarkers of  disease or relaco rilant treatment.  
x Samples may be retained for future determination of active metabolite concentrations and 
possible biomarkers related to drug response. 
10.3.2 Patient Confidentiality 
To maintain patient privacy, all source documents, study re ports, and communications will 
identify the patient by initials and the assigned patient number. The Investigator will grant 
monitor(s) and auditor(s) from the Sponsor or its designee and regulatory authority(ies) access to 
the patient‚Äôs original source records for data veri fication and to audit the data collection process. 
The patient‚Äôs confidentiality will be maintained and will not be made publicly available to the 
extent permitted by applicable laws and regulations. 
10.3.3 Patient Privacy 
The Investigator or designee must explain to ea ch patient, before enrollment into the study, that 
for evaluation of study results, the patient‚Äôs protected health information obtained during the 
study may be shared with the Sponsor or  its designee, regulatory agencies, and 
IRB/IEC/Research Ethics Board (REB). It is th e Investigator‚Äôs (or designee‚Äôs) responsibility to 
obtain written permission to use protected health  information per country-specific regulations 
from each patient or, if appropria te, the patient‚Äôs legally authorized representative. If permission 
to use protected health information is withdrawn, it  is the Investigator‚Äôs responsibility to obtain a 
written request, to ensure no further data will be collected from the patient, and the patient will be removed from the study. 
Written authorization is to be obtained from each patient before enrollment  into the study, and/or 
from the patient‚Äôs legally authorized representative in accordance with the applicable privacy 
requirements. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 85 of 105 11 ADMINISTRATIVE CONSIDERATIONS 
11.1 Study Monitoring 
Monitoring of the study site (including, but not  limited to, reviewing CRFs for accuracy and 
completeness, and assessing compliance with the protocol and adherence to regulatory and GCP 
requirements) will be perfor med by the Sponsor‚Äôs Clinical Monitor or designee.  
x Monitoring will be performed in accordance with applicable local and country 
regulations and guidance. 
x Monitoring will include regular site visits and communication with the Investigator and site staff as appropriate to  discuss and answer study ques tions; ensure compliance with 
the protocol; and ensure quality and integrity of the data.  
x Monitors will ensure the site maintains an adequate supply of st udy drugs; any necessary 
supplies and ensure that  appropriate storage c onditions are maintained. 
x Monitoring visits will be conducted accord ing to the US CFR Title 21 parts 50, 56, and 
312; and International C ouncil on Harmonisation (ICH) Guideline for GCP.  
Monitoring methods, responsibilities, and re quirements will be outlined in the study 
monitoring plan. 
11.2 Quality Management 
As part of quality management based on a risk-based approach per ICH E6(R2): 
Risk reduction activitie s may be incorporated in protocol design and implementation, 
monitoring plans, agreements between parties de fining roles and respons ibilities, systematic 
safeguards to ensure adherence to standard ope rating procedures, and training in processes 
and procedures.  
Predefined quality tolerance limits should be established, taking into consideration the 
medical and statistical characteristics of the variables as well as the statistical design of the 
trial, to identify systematic issues that can impact subject safety or reliability of trial results. 
Detection of deviations from the predefin ed quality tolerance limits should trigger an 
evaluation to determine if action is needed.  
Study sites, the study database, and study document ation will be monitored regularly and may be 
subject to a quality assurance (QA) audit dur ing the study by the Sponsor or its designee on 
behalf of the Sponsor. In addition, inspections may be  conducted by regulatory agencies at their 
discretion.  
Quality control (QC) procedures will be implemented beginning with the data entry system and 
data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
Following written SOPs, the monitors will verify that the clinical study is conducted, data are 
generated, documented (recorded), and reported in  compliance with the protocol, GCP, and the 
applicable regulatory requirements (e.g., Good Laboratory Practic es, Good Manufacturing 
Practices).  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 86 of 105 The investigator site will provide direct access to all trial-related sites, source data/documents, 
and reports for the purpose of monitoring and auditing by the Sponsor, and inspection by local 
and regulatory authorities. 
11.3 Documentation 
11.3.1 Case Report Forms and Study Records 
The Investigator must generate and maintain complete, adequate, accurate, reliable, and 
consistent records to enable full documentati on of study conduct. Study da ta will be captured on 
CRFs. Investigators must retain all original source documents. The Sponsor or its designee will 
notify Investigators in writing when the trial-related records are no longer needed.  
11.3.2 Access to Source Documentation 
The Sponsor or its representative will be allowed to c onduct site visits to the investigational 
facilities for the purpose of monitoring any aspect of the study. The Investigator agrees to allow 
the monitor to inspect the drug storage area, study-drug stocks, drug accountability records, 
patient charts and source documents, and other records relative to study conduct. 
By signing the protocol, the Principal Investigator agrees that, within local regulatory restrictions 
and institutional and ethical considerations, au thorized representatives of the Sponsor, a 
regulatory authority, and/or an IRB/IEC may vis it the site to perform audits or inspections, 
including the drug storage area, study-drug stocks, drug accountability records, patient charts and 
source documents, and other records relative to study conduct. The purpose of a Sponsor audit or 
inspection is to systematically and independently examine all study-related activities and 
documents (e.g., laboratory reports, x-rays, workbooks, patients‚Äô medical records) to determine whether these activities were conducted, and data recorded, an alyzed, and accurately reported 
according to the protocol, GCP guidelines of the ICH, and any applicable regulatory requirements.  
The Investigator should contact the Sponsor or  their designee immediat ely if contacted by a 
regulatory agency regarding an inspection. 
11.3.3 Source Documents 
Source documents provide all original records of clinical findings, observations, or other 
information from a clinical trial necessary for the reconstruction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, a patient‚Äôs 
medical records, hospital charts, clinic charts, the Investigator‚Äôs patient study files, as well as the results of diagnostic tests such as x-rays, laboratory tests, and ECGs. All data entered into the 
CRFs must be substantiate d by a source document. 
11.3.4 Study Files and Retention of Study Records 
The Investigator must maintain adequate and accurate records to  enable the conduct of the study 
to be fully documented and the study data to be subsequently verified.  
Study documents should be retained for a minimu m of 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 87 of 105 applications in an ICH region or until at least 2 years have elapsed since the formal 
discontinuation of clinical deve lopment of the study drug. These documents should be retained 
for a longer period, however, if required by loca l regulations. No records will be destroyed 
without the written consent of the Sponsor, if applicable. It is the responsibility of the Sponsor to 
inform the Investigator when these doc uments no longer need to be retained. 
Patient identification codes (pa tient names and corresponding study numbers) will be retained for 
this same period of time. These documents may be transferred to another responsible party, 
acceptable to the Sponsor, who agrees to abide by  the retention policies. Written notification of 
transfer must be submitted to the Sponsor. The In vestigator or designee must contact the Sponsor 
before disposing of any study records. 
11.4 Sample Collection, Preparation, and Shipping 
Instructions for collection, preparation, and shi pping of all laboratory sa mples will be provided 
in the study laboratory manual. 11.5 Long-Term Retention of Biological Samples 
All biological samples will be retained by Corcept or designee under the original informed 
consent of the patient and the IRB/IEC approval. Samples will be held for a period up to 20 years 
after acquisition. Corcept or the designee may stor e the patient‚Äôs sample(s) longer if required to 
address regulatory agency questions; in this event, the patient‚Äôs sample(s) will be destroyed after all questions are adequately answered.  
An individual patient can choose to  withdraw consent to have hi s/her samples used for future 
research at any time without affe cting their participation in the study or their care by the health 
provider. Upon receipt of a request for sample destruction, that patient‚Äôs sample(s) will then no 
longer be used for research purposes, and their sample(s) will be destroyed.  However, if there 
are ongoing regulatory questions, the patient‚Äôs sample (s) will be destroyed af ter all questions are 
adequately answered. 
The long-term retention samples w ill be coded to allow de-identification acco rding to applicable 
regulatory guidelines. It is the responsibility of the trial site to ensure that samples are 
appropriately labelled in accordance with trial procedures to comply with all applicable laws, 
which may include but are not limited to Europ ean Directives 95/46/EC and 2002/58/EC and any 
legislation and/or regulation implementing or made pursuant to th em, or which amends, replaces, 
re-enacts, or consolidates any of them, and all other applicable laws relating to processing of 
personal data and privacy that may exist in any relevant ju risdiction. Biological samples 
collected from participants as part of this  trial will be transpor ted, stored, accessed, and 
processed in accordance with all applicable laws  relating to the use and storage of human tissue 
for research purposes and such activities shall at least meet the requirements as set out in the 2004 Human Tissue Act and the 2006 Hu man Tissue (Scotland) Act. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 88 of 105 11.6 Clinical Supplies 
11.6.1 Inventory, Reconciliation, Return, and Disposition of Clinical Supplies 
All study drug and related materials should be stor ed, inventoried, reconc iled, and destroyed or 
returned according to applicable state and federal regulations a nd study procedures. Relacorilant 
and placebo equivalent, including dose and regimen, formulation, packaging, and storage, are 
described in Table 1 .  
11.6.2 Clinical-Suppl y Inventory 
A detailed inventory must be completed for all study drug. The study drug is to be used in 
accordance with the protocol by patients who are unde r the direct supervision of an Investigator. 
The study drug must be dispensed only by an appropriately qualified pe rson to patients in 
the study.  
Unused study drug must be kept in a secure location for accountability and reconciliation by the 
study monitor. The Investigator or designee must  provide an explanation for any destroyed or 
missing study drug or study materials. The Investigator or designee is responsible for maintaining accurate records (including dates and 
quantities) of study drug( s) received, patients to whom st udy drug is dispensed (patient-by-
patient dose specific accounting), and study drug lost or accidentally or deliberately destroyed. 
The Investigator or designee must retain a ll unused or expired study supplies until the study 
monitor (on-site CRA) has conf irmed the accountability data and Sponsor has approved return 
or destruction. 
11.6.3 Return or Disposal of St udy Drug and/or Supplies 
All clinical study drug and/or supplies will either be de stroyed by the site per institutional policy, 
or be returned to the Sponsor  or designee for destruction. 
Unused study drug may be destr oyed on site, per the site‚Äôs SOPs, but only after Sponsor has 
granted approval for drug destruction. The st udy monitor must account for all study drug in a 
formal reconciliation process, before study-dr ug destruction. All study drug destroyed on site 
must be documented.  
Documentation must be provided to the Sponsor and retained in the I nvestigator study files. 
If a site is unable to destroy st udy drug appropriately, the site can return unused study drug to the 
Sponsor upon request. The return of study drug or study-drug materials must be accounted for on 
a Study-drug Return Form provided by the Sponsor. 
11.7 Drug Accountability 
It is the responsibility of the Investigator to maintain drug accountability  at the study site and 
ensure that a current record of study-drug disposition is maintained. It is the responsibility of the 
Investigator to ensure that the study drug is us ed only in accordance with the approved protocol. 
This includes acknowledgment of  receipt of each shipment of study product (quantity and 
condition), patient dispensing records, and returned or destroyed study product.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 89 of 105 Dispensing records will document quantities re ceived from the Sponsor (or designee) and 
quantities dispensed to patients, including lot number, date dispensed, patient identifier number, 
patient initials, and th e initials of the person dispensing the drug.  
At the end of the study, after final drug invent ory reconciliation by the study monitor, the study 
site will dispose of and/or destroy all unused investigational medicinal pr oduct supplies, 
including empty containers, according to SOPs. 
11.8 Post-Trial Care 
Patients who successfully complete the clinical study will be permitted to continue relacorilant 
treatment in an extension study provided they have at least 80% adherence with scheduled 
dosing (by capsule counts).  
Patients who enroll in an extension study without interruption will not be required to complete 
the follow-up visit. The last study visit fo r these patients will be the Week 22 visit. 
11.9 Protocol Noncompliance 
Prospective approval of devia tions from the inclusion and excl usion criteria, also known as 
protocol waivers or exemptions, is not permitted. 
A protocol deviation is any noncom pliance with the clinical tria l protocol, GCP,  or manual of 
procedures (MOP) requirements. The noncompliance may be either on the pa rt of the patient, the 
Investigator, or the study site staff. As a re sult of deviations, corrective actions are to be 
developed by the site and impleme nted promptly. These practices are consistent with ICH E6.  
The Investigator should not imple ment any deviation from the prot ocol without prior review and 
agreement by the Sponsor in writing and in accord ance with the IEC/IRB and local regulations, 
except when necessary to eliminate an immediate hazard to study patients. When a deviation 
from the protocol is deemed necessary for an individual patient, the Investigator must obtain approval in writing from the Sponsor. 
Such contact must be made as soon as possible to permit a review by th e Sponsor to determine 
the impact of the deviation on the patient and/or the study. 
Any significant protocol deviations affecting patient eligibility and/or safety must be reviewed 
and/or approved by the IEC/IRB and regulatory authorities, as applicable, prior to 
implementation. 
11.10 Financial Disclosure 
Investigators will be required to  disclose any financia l equity interests in  the Sponsor and any 
conflicts of interest, as  defined by the Sponsor.  
11.11 Publication and Disclosure Policy 
Corcept, as the Sponsor, has a propr ietary interest in this study.  
No individual publications will be  allowed before publication of the multicenter results, except 
as agreed with Corcept. The Investigator agrees to submit all manuscripts or abstracts to Corcept 
for review before submission to the publisher. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 90 of 105 Corcept will comply with the requirements for pu blication of study results  and determination of 
authorship in accordance with standard editorial and ethical practice and with the International 
Committee of Medical Journal Editors (ICMJE) requirements. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 91 of 105 12 REFERENCES 
American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of 
medical care in diabet es‚Äî2020. Diabetes Care. Jan; 43(Suppl 1):  S98‚ÄìS110.  
Athimulam S, Bancos I. 2019. Evaluation of bone health in patients with adrenal tumors. Curr 
Opin Endocrinol Diabetes Obes. 26(3):125‚Äì132. doi: 10.1097/MED.0000000000000478. 
Bancos I, Alahdab F, Crowley RK, Chortis  V, Delivanis DA, Erickson D, et al. 2016. 
Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal 
tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis. Eur J 
Endocrinol. 175(6):R283 ‡ØÖR295. 
Beck AT, Steer RA, Brown GK. 1996. Beck Depression Inventory¬Æ-II (BDI¬Æ-II) Manual. 
Pearson Publishing Company, London, UK. 
Belokovskaya R, Ravikumar A, Arumugam D, Izadmehr S, Goddard GM, Geer EB, et al. 2019. 
Mifepristone treatment for mild autonomous co rtisol secretion due to adrenal adenomas: 
a pilot study. Endocr Pract. 25(8):846 ‡ØÖ853. doi: 10.4158/EP-2019-0047. 
Cerep Report 100011862. InV itro Pharmacology Study of CORT122928 and CORT125134. 
Study No. 100011862 - Version 1 - November 19, 2013.  
Chiodini I, Ramos-Rivera A, Marcus AO, Ya u H. 2019. Adrenal hypercortisolism: A closer look 
at screening, diagnosis, and important considerations of different testing modalities. J 
Endocr Soc. 3(5):1097‚Äì1109. doi: 10.1210/js.2018-00382. 
Corcept Therapeutics. 2020. CORT125134-451 Phase 2 Study of the Safety and Efficacy of 
CORT125134 in the Treatment of Endogenous Cushing‚Äôs Syndrome.  
Debono M, Chadarevian R, Eastell R, Ross RJ , Newell-Price J. 2013. Mifepristone reduces 
insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels 
of cortisol: a pilot study. PLoS One. 2013;8(4):e60984. doi: 
10.1371/journal.pone.0060984.  
Debono M, Bradburn M, Bull M, Harrison B, Ross  RJ, Newell-Price J. 2014. Cortisol as a 
marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab. 99(12):4462 ‡ØÖ4470. doi: 10.1210/jc.2014-3007. 
Dekkers OM, Horv√°th-Puho¬¥ E, J√∏rgensen JO, Ca nnegieter SC, Ehrenste in V, Vandenbroucke 
JP, et al. 2013. Multisystem morbidity and mo rtality in Cushing‚Äôs syndrome: a cohort 
study. J Clin Endocrinol Meta b. 98(6):2277‚Äì2284. doi: 10.1210/jc.2012-3582.  
Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, Prokop L, et al. 2019. Natural 
history of adrenal incidentalomas with a nd without mild autonomous cortisol excess: A 
systematic review a nd meta-analysis. Ann Intern Med. 171(2):107 ‡ØÖ116. doi: 
10.7326/M18-3630. 
EMA. 2022. European Medicines Agency Guidan ce on the Management of Clinical Trials 
during the COVID-19 (Coronavirus) Pande mic, Version 5 (10 February 2022). 
Fassnacht M, Arlt W, Bancos I, Dralle H, Newe ll-Price J, Sahdev A, et  al. 2016. Management of 
adrenal incidentalomas: European Society of  Endocrinology Clinical Practice Guideline 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 92 of 105 in collaboration with the European Networ k for the Study of Adrenal Tumors. Eur J 
Endocrinol. 175(2):G1‡ØÖ G34. doi: 10.1530/EJE-16-0467. 
FDA (US Food and Drug Administration). 2017. Guidance for Industry: Multiple Endpoints in 
Clinical Trials. Draft Guidance. January. 
FDA (US Food and Drug Administration). 2021. Conduc t of Clinical Trials  of Medical Products 
during the COVID-19 Public Health Emerge ncy. Guidance for Industry, Investigators, 
and Institutional Review Bo ards; updated on August 30, 2021. 
Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, et al. 2012. 
Mifepristone, a glucocorticoid receptor an tagonist, produces clin ical and metabolic 
benefits in patient s with Cushing's syndrome. J Clin Endocrinol Metab. 97(6):2039‚Äì2049. 
doi: 10.1210/jc.2011-3350. 
Giraldi FP, Pivonello R, Ambrogio AG, et  al. 2007. The dexame thasone-suppressed 
corticotropin-releasing hormone  stimulation test and the desm opressin test to distinguish 
Cushing‚Äôs syndrome from pseudo-Cushing‚Äôs states. Clin Endocrinol. 66:251‚Äì257. doi: 
10.1111/j.1365-2265.2006.02717.x. 
Hochberg Y. 1988. A sharper Bonferroni pro cedure for multiple tests of significance. 
Biometrika. 75:800‚Äì802.  
ICH E6, Guideline for good clinical practice E6(R2); 1 December 2016; principle 2.2.  
Morelli V, Eller-Vainicher C, Palmieri S, Ca iroli E, Salcuni AS, Scillitani A, et al. 2016. 
Prediction of vertebral fractur es in patients with monolateral adrenal incidentalomas. J 
Clin Endocrinol Metab. 101(7):2768-75. doi: 10.1210/jc.2016-1423.  
NCI (National Cancer Institu te). 2017. Common Terminology Criteria for Adverse Events 
(CTCAE), version 5.0 published: November  27, 2017. US Departme nt of Health and 
Human Services, National Institutes of Health, Accessed at 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf 
Nelson LM, Forsythe A, McLeod L, et al. 2013. Psychometric evaluation of the Cushing's 
Quality-of-Life questionnaire. Patie nt. 6(2):113‚Äì124. doi: 10.1007/s40271-013-0012-5. 
Parati G, Stergiou G, O‚ÄôBrien E, et al. 2014. European Society of Hypertension practice 
guidelines for ambulatory blood pressure  monitoring. J Hypertens. 32:1359‚Äì66. doi: 
10.1097/HJH.0000000000000221. 
Shepherd JA, Ng BK, Sommer MJ, Heymsf ield SB. 2017. Body composition by DXA. Bone. 
104:101‚Äì105. doi: 10.1016/j.bone.2017.06.010. 
Steingrimsson, Jon Arni et al. 2017. Improving precision by adjusting for prognostic baseline 
variables in randomized trials with bi nary outcomes, without regression model 
assumptions. Contemporary Clinical Trials. 54:18-24. 
Toniato A1, Merante-Boschin I, Opocher G, Pe lizzo MR, Schiavi F, Ballotta E. 2009. Surgical 
versus conservative management for subclinical Cushing syndrome in adrenal 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 93 of 105 incidentalomas: a prospective rando mized study. Ann Surg. 249(3):388‚Äì391. doi: 
10.1097/SLA.0b013e31819a47d2. 
Webb SM, Badia X, Barahona MJ, et al. 2008. Ev aluation of health-related quality of life 
in patients with Cushing‚Äôs syndrome with  a new questionnaire. Eur J Endocrinol. 
158:623‚Äì630. doi: 10.1530/EJE-07-0762. 
Yanovski JA, Cutler Jr GB, Chrousos GP, et  al. 1993. Corticotropin-releasing hormone 
stimulation following low-dose dexamethasone ad ministration: a new test to distinguish 
Cushing‚Äôs syndrome from pseudo-Cush ing‚Äôs states. JAMA. 269(17):2232‚Äì2238. 
Yanovski JA, Cutler Jr GB, Chrousos GP , et al. 1998. The dexamethasone-suppressed 
corticotropin-releasing hormone stimulation test differentiates mild Cushing‚Äôs disease 
from normal physiology. J Clin E ndocrinol Metab. 83(2):348‚Äì352. doi: 
10.1210/jcem.83.2.4568. 
Zografos GN, Perysinakis I, Vassilatou E. 2014. Subclinical Cushing's syndrome: current 
concepts and trends. Hormones (Athens). 2014. 13(3):323 ‡ØÖ337. doi: 
10.14310/horm.2002.1506. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 94 of 105 APPENDICES  
 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 95 of 105 Appendix A: Schedule(s) of Activities 
Table 11 Schedule of Clinical Assessments and Procedures 
Study Procedure Screening a Baseline Double-Blind, Pl acebo-Controlled 
Weeks 1 to 22 Early 
Termination Follow-up b 
Visit Name ‚Äî ‚Äî Week 2 Week 6 Week 10 Week 14 Week 18 Week 22 ET ‚Äî 
Visit Number 1 2 3 4 5 6 7 8 9 10 
Visit Window (d) √≠ WR √≠  ‚Äî ¬±7d ¬±7d ¬±7d ¬±7d ¬±7d -14/+7d +14d ¬±7d 
Informed consent X - - - - - - - - - 
Inclusion/exclusion criteria X X - - - - - - - - 
Medical and medication history c X X - - - - - - - - 
Demographics/baseline disease 
characteristics X X - - - - - - - - 
Physical examination d X X X X X X X X X X 
Height, weight, waist circumference 
e X X X X X X X X X X 
Vital signs f X X X X X X X X X X 
Adverse events g - X X X X X X X X X 
Concomitant medications X X X X X X X X X X 
12-Lead ECG (in duplicate) X - - - - X - X X - 
Pregnancy test (women only) h X (s) X (u) X (u) X (u) X (u) X (u) X (u) X (u) X (u) X (u) 
Chemistry i, Hematology j X X X X X X X X X X 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 96 of 105 Study Procedure Screening a Baseline Double-Blind, Pl acebo-Controlled 
Weeks 1 to 22 Early 
Termination Follow-up b 
Visit Name ‚Äî ‚Äî Week 2 Week 6 Week 10 Week 14 Week 18 Week 22 ET ‚Äî 
Visit Number 1 2 3 4 5 6 7 8 9 10 
Visit Window (d) √≠ WR √≠  ‚Äî ¬±7d ¬±7d ¬±7d ¬±7d ¬±7d -14/+7d +14d ¬±7d 
Lipid-metabolism panel (fasting) k - X - - - - - X X - 
Thyroid-function tests X - - - - - - - - - 
Coagulation panel l - X - - - X - X X - 
Serum osteocalcin - X - - - - - X X - 
GR activity biomarker tests X - - X X X - X X - 
2-hour oGTT m X X n X X X X X X X - 
HbA1c o X X n - - X - - X X - 
HPA-axis parameters p X - - X X X - X X - 
24-hour UFC with creatinine q X - - - - - - - - - 
DST with dexamethasone levels r X - - - - - - - - - 
Late-night salivary cortisol s X - - X X X - X X - 
Early-morning salivary cortisol t X X - X X X X X X - 
ABPM (24-hour) test u X - X X X X X X v X - 
DXA scan w  - X w - - - - - X X w - 
Pharmacokinetics, intensive - - - - - - X - - - 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 97 of 105 Study Procedure Screening a Baseline Double-Blind, Pl acebo-Controlled 
Weeks 1 to 22 Early 
Termination Follow-up b 
Visit Name ‚Äî ‚Äî Week 2 Week 6 Week 10 Week 14 Week 18 Week 22 ET ‚Äî 
Visit Number 1 2 3 4 5 6 7 8 9 10 
Visit Window (d) √≠ WR √≠  ‚Äî ¬±7d ¬±7d ¬±7d ¬±7d ¬±7d -14/+7d +14d ¬±7d 
Cushing QoL questionnaire  - X - X X X X X X - 
Beck Depression Inventory  - X - X X X X X X - 
Sit-to-stand test - X - X X X X X X - 
Trail-making test - X - X X X X X X - 
Dosing diary - X X X X X X - - - 
Study-drug dispensing and/or 
adherence x - X X X X X X X y X - 
ABPM, ambulatory blood pressure monitoring;  BP, blood pressure; DST, dexamethasone suppression test; DXA, dual-energy X-ray abs orptiometry, ECG, 
electrocardiogram; ET, early termination; GR, glucocorticoid receptor; HbA1c, hemogl obin A1c; HPA, hypotha lamic-pituitary-adren al; oGTT, oral glucose 
tolerance test; QoL, quality-of-life; (s), serum; (u), urine; UFC, urinary free cortisol. 
 
a. All assessments done during Screening can be used as Baseline with the exception of oGTT, HbA1c, and 24-hour ABPM, which mus t be performed within 
2 weeks of the Baseline Visit and used as Baseline. Medications used in the treatment of Cushing syndrome are prohibited and require washout of at least 
12 weeks before Screening. 
b. For patients who do not enroll in an extension study, the Follow-up visit will occur 28 days after the last dose of study dr ug. 
c. For any medication used to treat hypercortisolism, hypertension, and/or diabetes 3 months prior to Day 1. 
d. General physical appearance of patients during the examination will be assessed.  
e. Height is measured at Screening only. Body weight and circumference will be measured at all visits. 
f. Vital signs: BP, heart rate, respiratory rate, and body temperature. 
g. Adverse events will be collected after the informed consent fo rm is signed. Events ongoing at study entry are considered med ical history.  
h. Pregnancy tests: for women of childbearing potential: (s)=serum pregnancy test at Screening; (u)=urine pregnancy test at oth er time points. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 98 of 105 i. Chemistry parameters: full chemistry profile that includes albumin, alkaline phosphatase, ALT, AST, bicarbonate, blood urea nitrogen, calcium, chloride, 
cholesterol, creatinine, fasting glucose, fasting insulin, lactate dehydrogenase, magnesium, phosphorus, potassium, sodium, cre atine kinase, total and direct 
ELOLUXELQ WRWDOSURWHLQXULF DFLG 6KRXOGEH SHUIRUPHG HLWKHUEHIRUHRU¬ïK ours after, the DST test. 
j. +HPDWRORJ\SDUDPHWHUVD FRPSOHWH EORRG FRXQWDQGGLIIHUHQWLDO 6KRXOGEH SHUIRUPHG HLWKHU EHIRUH RU ¬ï K ours after, the DST test. 
k. Lipid-metabolism panel: total cholesterol, low-density lipoprot ein-cholesterol, high-density lipoprotein-cholesterol, very l ow-density lipoprotein-cholesterol, 
DQG WULJO\FHULGHV 6KRXOGEH SHUIRUPHG HLWKHUEHIRUH RU¬ïKours after, the DST test. 
l. Coagulation panel: Factor VIII, von Willebrand factor, protein S, protein C, thrombin antithrombin (TAT), and partial thromb oplastin time (PTT). Should be 
SHUIRUPHG HLWKHUEHIRUH RU ¬ï K ours after, the DST test. 
m. oGTT, including measurement of glucagon levels at selected visits (i.e., Baseline Visit, Week 10, Week 22, and ET Visit [if applicable]; for patients with 
DM/IGT at Baseline): The 2-hour oGTT will be performed on all patients during Screening. During Screening, oGTT should be perfo rmed either before, or 
¬ïhours after, the DST test. In patients with an increase to their '0 PHGLFDWLRQVEHIRUHRU GXULQJ 6FUHHQLQJR*77 VKRXOG EHSHUIR UPHG¬ï ZHHNVDIWHU
the increase. The Screening 2-hour oGTT must be performed within 2 weeks of the Baseline Visit and used as Baseline. During treatment with study drug, a 
2-hour oGTT will be performed only in patients with DM/IGT except at the Baseline Visit, Week 10, Week 22 and ET Visit (if appl icable), when the 2-hour 
oGTT will be performed for all patients.  
n. oGTT and HbA1c will only be performed at Baseline if the prior assessment was not performed within 2 weeks. 
o. HbA1c: The HbA1c test will be performed on all patients during Screening. In patients who have an increase to their DM medic ations before or during 
6FUHHQLQJ +E$FVKRXOGEH SHUIRUPHG ¬ïZHHNVDIWHU the increase in the diabetes medication. The Screening HbA1c test must be performed within 2 weeks 
of the Baseline Visit and used as Baseline. During treatment with study drug, HbA1c will be performed only in patients with DM/ IGT except at the Baseline 
Visit, Week 10, Week 22 and ET Visit (if applicable), when the HbA1c test will be performed for all patients. 
p. HPA-axis: Early-morning plasma ACTH, fasting serum cortisol, and DHEA-S. HPA- D[LVWHVWVVKRXOG EH SHUIRUPHGHLWKHU EHIRUH RU¬ï hours after, the 
DST test. ACTH should be measured at least twice during Screening. 
q. 24-hour UFC test samples will be collected by the patient at home twice during Screening. The average of the results will se rve as Baseline. UFC collection 
VKRXOG EHSHUIRUPHGHLWKHU EHIRUH RU ¬ï hours after, the DST test. 
r. DST: 1-mg overnight or 2-mg 48-hour dexamethasone test must  be performed during Screening. Dexamethasone levels should be me asured concurrently. 
Estrogen preparations, including birth control and hormone replacement treatments, should be withheld for a duration of at least 5 half-lives of the estrogen 
analogue prior to DST. 
s. Two late-night salivary cortisol samples will be collected at Screening, one of which should be the night before the Day 1/B aseline Visit. During treatment 
with study drug, a late-night salivary-cortisol sample should be collected the night before the study visit. During Screening, salivary cortisol sample 
FROOHFWLRQ VKRXOGEH SHUIRUPHG HLWKHU EHIRUHRU ¬ï hours after, the DST test. 
t. Early-morning salivary cortisol will be collected at the site if the patient arrives before 9 am (to avoid mix up with the l ate-night salivary cortisol samples 
collected by the patient). If the visit is scheduled after 9 am, the sample will be collected at home by the patient the mornin g of the visit. Early-morning 
salivary cortisol should be collected either on the same day as the late-night salivary cortisol is collected, or the morning a fter.  
u. ABPM: The 24-hour ABPM will be assessed for all patients duri ng Screening. During Screening, in patients with an increase to  their anti-hypertension 
medications either before or during Screening, ABPM VKRXOG EH SHUIRUPHG ¬ï ZHHNVDIWHUWKH increase in anti-hypertension medications. During Screening, 
ABPM VKRXOG EH SHUIRUPHG HLWKHU EHIRUH RU ¬ï hours after, the DST test. ABPM must be performed within 2 weeks of the Baseline Visit and used as 
Baseline. During the study, ABPM measurements will be performed only for patients with systolic  hypertension except at Week 10,  Week 22, and ET Visit 
(if applicable), when ABPM will be performed for all patients.  
v. Week 22 visit ABPM should be performed within 7 days prior to the visit.  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 99 of 105 w. DXA scan should be performed within 2 weeks of the Baseline Visit. Patients to get DXA scan before Baseline Visit only in th e case they are already 
determined to qualify for the study. At ET vi sit (if applicable), DXA scan should not be  repeated if it was already completed w ithin 8 weeks prior to ET 
Visit; acceptable visit window is up to 3 months following ET Visit. 
x. At ET visit, only study adherence needs to be performed; no  study drug should be dispensed. Administration of study drug is the last procedure at applicable 
visits, other than the Week 18 visit, when it should be administered prior to blood draws for PK assessment. 
y. Patients will remain on study drug post Week 22 until it has been confirmed that all results for efficacy assessments are av ailable and no repeated 
assessments are required. 
 
 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 100 of 105 Appendix B: Summary of Changes 
Significant changes in Amendment 3 of the pr otocol dated 11 October 2024 compared with 
Amendment 2 dated 21 June 2023 are summari zed below with a dditional details in  Table 12 ; 
deleted text is shown as a strike through and new text is shown in bold .  
Minor editorial or stylistic changes made for consistency are not summa rized and may not be 
shown in the redline version of the amendm ent (e.g., punctuation, sp elling, abbreviations). 
Throughout the document, sections, tables, and figu res were renumbered as appropriate. Table of 
Contents, lists of tables or fi gures are updated without redline. 
Significant revisions to the pr otocol include the following: 
x Assessment of glycemic cont rol was moved from a primary to secondary objective 
x Primary and secondary endpoints are update d to align with the revision to study 
objectives  
x Statistical analyses secti ons are updated to align with revisions to endpoints  
x Imputation methods for missing da ta related to the primary analysis are updated to use a 
placebo wash-out multiple imputation method 
x Endpoints for hyperglycemia are updated to in clude additional continuous endpoints   
x Statistical analyses sections are updated to reflect gated testing approach of certain 
secondary endpoints  
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 101 of 105 Table 12 Summary of Changes in Pr otocol CORT125134-456 Amendment 3  
Section Summary of Change Revisions 
Throughout the 
protocol Updated version and date of the protocol. Amendment 2 3 
21 June 202311 October 2024  
Title page Updated Sponsor address Corcept Therapeutics Incorporated 
149 Commonwealth Drive 
Menlo Park 101 Redwood Shores Parkway 
Redwood City, California 94025 94065 USA 
(650) 327-3270 
Synopsis Updated text in synopsis revised to align with changes in the protocol body. -- 
Throughout the protocol Updated text throughout to present hypertension before DM/IGT for consistency with revisions to endpoints -- 
2.1 Primary Objectives Updated to remove glycemic control as a primary objective To assess the efficacy of rela corilant for the treatment of 
hypercortisolism in patients with cortisol-secreting adrenal 
adenomas or hyperplasia, based on glycemic and blood 
pressure (BP) control at Week 22 compared with placebo 
2.2 Secondary 
Objectives Updated to include glycemic control as a secondary objective To assess changes in cortisol excess-related comorbidities 
(e.g., body weight and glycemic control ) in patients with 
hypercortisolism due to cortisol-secreting adrenal adenomas/hyperplasia 
3.2.1 Primary 
Endpoints Updated to remove measure of AUC
glucose  (glycemic 
control) as a primary endpoint In patients with DM/IGT, the mean change in AUCglucose, 
from Baseline to Week 22 as compared between relacorilant 
and placebo arms. 
3.2.2 Secondary Endpoints  Updated to include AUC
glucose  as a secondary 
endpoint for hyperglycemia 1. In patients with DM/IGT at Baseline, the mean change in AUC
glucose , from Baseline to Week 22 as compared 
between relacorilant and placebo arms. 
Added additional continuous endpoints for hyperglycemia 9. In patients with DM/IGT in the ITT population, the proportion of pa tients who achiev ed decrease of 
AUC
glucose  RI ¬ï ¬ï ¬ï DQG DQ\ GHFUHDVH IURP
Baseline to Week 22. 
10. In patients with DM/IGT in the ITT population, the 
mean change in 2-hour oGTT 2-hour timepoint from Baseline to Week 22. 
7.11. In patients with DM/IGT in the ITT population, the 
mean change in 2-hour oGTT predrink timepoint from 
Baseline to Week 22.  
9.1 Analysis Populations Updated Table 10 to remove AUC
glucose  named as a 
primary endpoint  The mITT population will include all patients in the ITT SRSXODWLRQ ZLWK ¬ïSRVW -randomization efficacy assessment 
the primary and secondary  efficacy endpoints of ABPM  
and/or  AUC
glucose or ABPM). . This population will be used 
for sensitivity analyses performed on the primary and 
secondary efficacy endpoints. The mITT population can 
vary for different efficacy endpoints.  
Protocol CORT125134-456
Corcept Therapeutics Incorporated Amendment 3  |  11 October 2024
Confidential Page 102 of 105Section Summary of Change Revisions
9.2 General Statistical ConsiderationsRevised timing for finalization of the statistical analysis planStatistical methods will be prespecified and documented in detail in a statistical analysis plan, to be finalized before database lock study unblinding .
9.3 Hypothesis TestingUpdated section to describe gated testing approach forcertain secondary endpointsFor the testing of the primary and certain secondary 
efficacy endpoints, adjustment for multiplicity will be implemented to maintain a 2-sided 0.05 significance level for the Family-Wise type I error rate. 
In order to provide strong control of the Type I error, 
certain secondary analyses will  be tested using a gated 
testing approach at a 2-sided alpha level of 0.05. If the 
null hypothesis is rejected for the primary endpoint, certain secondary endpoints will be sequentially tested following the gatekeeping hi erarchy (Figure 2). No 
adjustments for multiplicity will be made for other secondary or exploratory endpoints. 
Figure 2: Sequential Gatekeeping Hierarchy  
Primary efficacy endpoints are defined in Section 3.2.1 3.2.1 . 
The study will be considered to have a positive outcome if 
either of the 2 primary endpoints reaches statistical 
significance.
To adjust for multiplicity for the 2 primary efficacy 
endpoints, a Hochberg step up procedure (Hochberg 1988; 
FDA 2017) will be conducted as follows: 
1. At the first step of the procedure, the larger 2-sided 
p-value of the 2 primary endpoints will be 
compared with the 0.05 significance level. 
2. If the larger p-value is <0.05, responses with 
respect to both glycemic control and hypertension 
will be declared statistically significant.

Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 103 of 105 Section Summary of Change Revisions 
3. If the larger p-value is >0.05, the other primary 
endpoint will be declared statistically significant if 
the corresponding 2-sided p-value is <0.025.  
4. Otherwise, neither of the 2 primary endpoint results 
will be considered statistically significant. 
All statistical hypotheses for any other  secondary endpoints  
and exploratory endpoints will be tested at a 2-sided 0.05 significance level unless otherwise specified.  
9.5.4.1 Analysis 
of Primary 
Efficacy Endpoint Removed analysis of 
glycemic control 
(AUCglucose) from primary 
analysis and revised 
imputation methods for missing data related For the DM/IGT subgroup, the estimand of interest is the 
between-treatment difference in change in AUCglucose 
from Randomization to Week 22 (estimated using a mixed 
model for repeated measures [MMRM] model). All 
available values for AUCglucose will be used for analysis in 
the MMRM model, regardless of treatment adherence.  
If there are a sufficient number of retrieved dropouts (at least 
10 patients who discontinue treatment but still had an 
AUCglucose assessment at Week 22), imputation of missing 
data at Week 22 (for non-retrieved dropouts) will be 
performed based on known measurements from the retrieved 
dropouts with similar baseline characteristics for patients 
discontinuing the study without use of rescue medication, 
but placebo-mean imputation at visits after initiation of 
rescue medication for patients that use rescue medication.  
For patients who use rescue medication for hyperglycemia 
control before Week 22, the plasma 2-hours oGTT test 
values collected after first use of rescue medication will not 
be included in the primary analysis. Rather, patients who use 
rescue medication for hyperglycemia control are assumed to 
perform similarly to patients who received placebo. And, 
therefore, the missing AUCglucose values after initiation of 
rescue medication in patients treated with relacorilant that 
receive diabetes rescue medi cation are replaced with the 
estimated mean of the entire endpoint distribution of the 
placebo arm at visits after initiation of rescue medication 
(this is the placebo-based mean value at each visit). 
The primary efficacy analysis for the primary endpoint of 
change in AUCglucose from Randomization to Week 22 
will be performed using a linear mixed-model-for-repeated-
measures (MMRM) using data with the imputation method 
described above. Restricted maximum likelihood (REML) 
estimation will be used. The MMRM model will include 
Baseline AUCglucose as a covari ate; treatment, visit, and 
treatment by visit interaction, and stratification factor as 
fixed effects; patients within treatment groups as random 
effects. In the DM/IGT subgroup, the stratification factor at 
randomization identifies patients with or without 
hypertension. An unstructured covariance structure will be 
used to model within-patient error, and the Kenward Roger 
approximation will be used to model denominator degrees of 
freedom. 
The primary analysis will de termine whether there is a 
difference between treatment groups in terms of change in 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 104 of 105 Section Summary of Change Revisions 
AUCglucose from Randomization to Week 22. This will be 
accomplished by using appropriate linear contrasts of the 
parameters in the MMRM model described above. 
Multiple imputation will be implemented to allow additional 
source of variability in the imputed values. For each imputed 
dataset, the same MMRM model specified above will be 
used to estimate treatment effect on change in AUCglucose 
from Randomization to Week 22. The combination of 
individual estimates for treatme nt effect and the inference 
based on the combined estimate will be handled by SAS 
procedure MIANALYZE. Additional sensitivity analyses 
will be specified in the statistical analysis plan (SAP). 
For the hypertension subgroup of the ITT Population , the 
estimand of interest is the between-treatment difference in 
change in average SBP based on 24-hour ABPM from 
Randomization to Week 22 (estimated using a MMRM 
model). All available values for SBP will be used for analysis in the MMRM model, regardless of treatment adherence. 
If there are a sufficient number of retrieved dropouts (at least 
10 patients who discontinue treatment but still had an SBP 
assessment at Week 22), imputation of missing data at 
Week 22 (for non-retrieved dropouts) will be performed 
based on known measurements from the retrieved dropouts 
with similar baseline characteristics for patients 
discontinuing the study without use of rescue medication, 
but placebo-mean imputation at visits after initiation of 
rescue medication for patients that use rescue medication. 
For patients who use rescue medication or discontinue 
treatment early, a placebo wa sh-out multiple imputation 
will be used as the primary analysis. For those patients 
who use rescue medication for hypertension after 
randomization and before Vi sit Week 22, the values 
collected after first use of  rescue medication are 
irrelevant to the clinical question of interest and will not be used in the analysis. For patients who discontinue treatment early, all collected  values (including retrieved 
drop-outs) will be used in the analysis. For patients who 
use rescue medication for hypertension control before Week 
22, the average SBP based on 24-hour ABPM collected after 
first use of rescue medication will not be included in the 
primary analysis. Rather, patients who use rescue medication 
for hypertension control are assumed to perform similarly to 
patients who received placebo. And, therefore, the missing 
average SBP after initiation of rescue medication in patients 
treated with relacorilant that  receive hypertension rescue 
medication are replaced with the estimated mean of the 
entire endpoint distribution of the placebo arm at visits after 
initiation of rescue medication (this is the placebo-based 
mean value at each visit). The ‚Äòplacebo wash-out‚Äô analysis 
means the missing 24-hour average SBP at Visit Week 22 
data will be imputed by considering a wash-out of the 
effect of treatment using comp leters in the placebo arm. 
Protocol CORT125134-456 
Corcept Therapeutics Incorporated  Amendment 3  |  11 October 2024 
Confidential Page 105 of 105 Section Summary of Change Revisions 
Specifically, 24-hour average SBP data for patients on the placebo arm without meas urements at Week 22 will 
be imputed using a monotone regression model based on observed 24-hour av erage SBP data of completers on the 
placebo arm with intermedia te measurements, Baseline 
value and stratification factor. For patients on the 
relacorilant arm with missing Week 22 data, the 
imputation model with only Baseline value and stratification factor will be used. 
‚Ä¶ 
Additional sensitivity analyses of the primary endpoint, 
including subgroups of interest , will be specified in the 
SAP. Additional sensitivity analyses of the primary endpoints by 
subgroups of interest will be done. Details will be described 
in the SAP. 
9.5.7 PD 
Analysis Revised timing for finalization of the statistical analysis plan Analysis of PD endpoints will be described in a separate PD 
analysis plan finalized before database lock study 
unblinding . 
9.5.8 Biomarker/ 
Pharmacogenetic Analysis  Revised timing for finalization of the statistical analysis plan Biomarker and pharmacogenetic exploratory analyses will 
be described in the SAP finalized before database lock study 
unblinding . 
 